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ABSTRACT 
Severe Acute Respiratory Syndrome (SARS) is a novel disease that induced 
a global tragedy in 2003. Totally, 916 human deaths were resulted and more than U.S. 
$30 billions were lost worldwide. The pathogen was discovered and named SARS-
associated coronavirus (SARS-CoV). The spike glycoprotein, one of the four known 
structural proteins, is related to viral entry, host range, tissue tropism and virulence. 
This glycoprotein has two functional subunits SI and S2, and they are responsible for 
receptor-binding and membrane fusion respectively. Nonetheless, the viral entry 
mechanism is not yet fully understood. Identification of the interacting partners 
might be helpful to find out the mechanism of the SARS pathogenesis and, in turn, 
develop an effective neutralizing vaccine against SARS-CoV. 
At present, two functional receptors, angiotensin-converting enzyme 2 (ACE2) 
and CD209L, are identified. Tissue distributions of these receptors are however 
different from that of SARS-CoV. Some tissues highly expressing ACE2 and 
CD209L are insusceptible. So, we believe that other unidentified receptor(s) or 
co-receptor(s) remain to be discovered. 
In this study, various DNA fragments encoding truncated spike proteins were 
cloned into pGEX-6P-l, pET-28a, pRHisMBP and pPICZa-A. The truncated 
proteins were then expressed in E. coli and P. pastoris expression systems. After 
optimizing the conditions of the protein expression, the truncated proteins were 
expressed on a large scale and purified. Pull-down assay was performed to screen 
interacting partners in the total lysate and membrane-enhanced fractions of 
SARS-CoV susceptible cells. Afterwards, potential partners were identified by 
two-dimensional gel electrophoresis and mass spectrometry. Up till now, when 
iii 
glutathione S-transferase (GST)-Sl was acted as bait, four potential interacting 
partners, but not ACE2 or other membranous protein, were identified. One of them is 
peroxiredoxin 1 binding to GST while others are chaperones including heat shock 
70 kDa protein, GroEL and DnaJ. On the other hand, by using receptor binding 
domain expressed in P. pastoris, ACE2 was detected by western blotting, suggesting 



















爲止，當glutathione S-transferase (GST)-Sl作爲誘館，已經發現四個可能的 
互動伙伴，但並不包括ACE2或任何細胞膜蛋白，其中一個是與GST連結的 
過氧化物酶1 ’而另外三個伴侶蛋白分別是熱休克蛋白70 ’ G r o E L及D n a J � 
XV 
. 另—；^面，利用P. pastoris所表達的受體結合功能區，ACE2可被西方轉漬法 
.丨偵測，由此推想，拉下實驗可成功捕獲真正的互動伙伴。 
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1.1.1 Outbreak and Influence 
On 16 November 2002, the first case of severe atypical pneumonia of 
unknown cause in the world was reported for the Guangdong Province, Southern 
China (Zhao et al.’ 2003b). After three months of the first reported case, outbreak of 
this atypical pneumonia had been occurred in Guangdong Province that the patient 
number was raised to 305 [World Health Organization (WHO), 2003a; WHO, 2003b; 
Zhong et al, 2003]. Meanwhile, cases from other countries and regions including 
Hong Kong, Vietnam, Canada and Singapore were reported (Centers for Disease 
Control and Prevention, 2003; Lee et al, 2003; Poutanen et al., 2003; Reilley et al” 
2003). This novel atypical pneumonia was later named Severe Acute Respiratory 
Syndrome (SARS) by WHO. SARS patients were treated by various drugs, 
for instance, interferons, ribavirin and human immunodeficiency virus (HIV) 
protease inhibitors, that were however not highly effective (Cinatl et al, 2004). 
Up to 5 July 2003, absence of new reported case represented SARS outbreak 
termination. Within eight months, cumulatively 8,422 patients from 32 countries or 
regions were infected and 916 of them were dead (Table 1.1) (WHO, 2003c). 
The average case-fatality ratio (CFR)，which measures the patients who die 
from a disease and reflects virulence, in the world was 11 %. Mainland China had 
the highest SARS patient number, which was 5,327, while the region of the highest 
attack rate was Hong Kong, which 25.6 inhabitants were infected in every 100,000 
inhabitants (Figure 1.1) (WHO, 2003c). Besides lives loss, SARS induced loss of 




Table 1.1 - The numbers, ages and CFRs of SARS patients in selected areas. 
Female and male cumulative numbers of cases from Mainland China were excluded 
(Adapted and modified from http://www.who.int/csr/sars/country/en/country2003_ 
08_15.pdf). 一 
Areas Cumulative number of cases Median age CFR 
Female Male Total — (range) (%) 
China / / 5327 Pending 7 
Hong Kong 977 778 1755 40 (0-100) 17 
Taiwan 349 319 665 46(2-79) 27 
Canada 151 100 251 49(1-98) 17 
Singapore 161 77 238 35 (1-90) 14 
Vietnam 39 24 63 43 (20-76) 8 
United States 16 17 33 36 (0-83) 0 
Philippines 8 6 14 41 (29-73) 14 
Germany 4 5 9 44 (4-73) 0 
Mongolia 8 1 9 32 (17-63) 0 
Thailand 5 4 9 42 (2-79) 22 
France 1 6 7 49 (26-61) 14 
Australia 4 2 6 15 (1-45) 0 
Malaysia 1 4 5 30 (26-84) 40 
Italy 1 3 4 30.5 (25-54) 0 
United Kingdom 2 2 4 59 (28-74) 0 
India 0 3 3 25 (25-30) 0 
Korea 0 3 3 40 (20-80) 0 
Sweden 1 2 3 33 0 
Indonesia 0 2 2 56 (47-65) 0 
Brazil 1 0 1 4 0 
Macao 0 1 1 28 0 
Colombia 1 0 1 28 0 
Finland 0 1 1 24 0 
Kuwait 1 0 i ^ 0 
New Zealand 1 0 1 67 0 
Ireland 0 1 1 56 0 
Romania O i l 52 0 
Russian 0 1 1 25 0 
South Africa 0 1 1 62 100 
Spain O i l 33 0 
Switzerland 0 1 1 ^ 0 
Total 1732 1366 8422 / 11 
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Selected sites Figure 1.1 一 The numbers and attack rates of SARS patients in selected sites. (A) The SARS patient number and (B) atta k rate  in selected s tes were shownThe highest SARS patient number was in Beijing while the highest attack rate was inHong Kong (Ada ted a d modified from http://www.who.int/csr/sars/ nAVHOconsensus.pdf).
3 
INTRODUCTION 
1,1.2 Clinical Features 
Cases of SARS patients in all ages had been reported. A possible reason for 
the slightly higher number of female patients was the higher chance of exposure 
among nurses (Donnelly et al, 2003). The incubation period was between two and 
ten days while its average was five days (Chan et al” 2004b; Chan-Yeung et al., 
2003; 丁sang et al, 2003; Wu et al, 2003; Zhao et al, 2003a). Fever presented in 
more than 99 % of the patients was the most common symptom. Cough, malaise and 
chill presented in 65.5 %, 58.8 % and 51.5 % of the patients respectively were also 
usual. Others such as myalgia, dyspnea and tachycardia were detected in 
some patients (Table 1.2) (Lee et al, 2003; Peiris et al, 2003a; Peiris et al., 2003b; 
Zhao et al, 2003a). 
Table 1.2 - Sexes, clinical features and physical signs of selected SARS patients 
(Adapted and modified from Peiris et al.’ 2003a). 
No. of patient No. of total Percentage 
with symptom patient 
Sex of patients 
Male 343 45.6 
Female 409 54.4 
Clinical features 
Fever 751 752 99.9 
Cough 460 702 65.5 
Malaise 317 539 58.8 
Chill or rigors 377 732 51.5 
Myalgia 365 752 48.5 
Dyspnea 282 614 45.9 
Dizziness 163 597 27.3 • 
Nausea or vomiting 8 30 26.7 
Chest pain or pleurisy 47 210 22.4 
Diarrhea 130 647 20.1 
Anorexia 37 188 19.7 
Headache 292 752 18.8 
Sore throat 91 552 16.5 
Rhinorrhoea 50 362 13.8 
Physical signs 
Tachycardia 71 154 46.1 
Tachypnea 60 154 39.0 




1.2.1 Genomic Organization 
The pathogen of SARS is a novel coronavirus (CoV) named SARS-
associated CoV (SARS-CoV), which was isolated from SARS patients (Drosten 
et cd” 2003; Ksiazek et aL, 2003; Peiris et al., 2003b). Experimental data also 
demonstrated that SARS-CoV is the cause of SARS (Fouchier et al., 2003; Kuiken 
et al.’ 2003). The viral genetic material of 30 kilobase pairs (kb) is single-stranded 
plus sense ribonucleic acid (RNA) possessing 15 putative open reading frames 
(ORFs) (Table 1.3) (Ksiazek et al.，2003; Marra et al； 2003'; Rota et al., 2003; Thiel 
et al., 2003; Zeng et al., 2003). 
Among these ORFs, ORFla and ORFlb comprising approximately 
two-thirds of the genome are translated to two polyproteins that are divided into 
a number of replicases by proteolytic processing. These replicases include RNA-
dependent RNA polymerase (POL), RNA helicase (HEL) and papain-like proteinase 
(3CLpr。）(Gao et al•，2003a; Snijder et al., 2003; Thiel et al, 2003). Their functions 
are replication of viral RNA and proteins, but the detailed replication mechanisms 
are not fully understood. 
Another four ORFs encoding structural proteins, spike (S)，envelop (E), 
membrane (M) and nucleocapsid (N) proteins can be found in the SARS-CoV 
genome. The major role of N protein is the association with viral RNA, leading to 
helical N formation (Chang et al., 2006; Hsieh et aL, 2005; Huang et aL, 2004). 
Abundant M protein binding to S, E and N proteins comprises intracellular 
membrane of SARS-CoV (Fang et al, 2005; He et al., 2004; Lee et al” 2005; Luo 
et aL, 2006). Besides M protein, E protein is another essential component 
constructing the viral membrane and binding to S protein (Ho et al., 2004b; Wu et al” 
5 
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2003). Finally, S protein, a transmembrane (TM) protein located at the viral 
membrane, can bind to cellular receptor and mediate viral entry (Giroglou et al., 
2004; He et al.’ 2006; Sainz et al., 2006; Yeung et al., 2006). 
In addition, nine putative accessory proteins of more than 50 amino acid (a. a.) 
residues are predicted to be translated though their presence and functions are still 
under investigation. Lastly, s2m motif, a conserved RNA sequence found in other 
CoVs, was detected at the 3' regions of the genomes of all SARS-CoV strains 
(Robertson et al” 2005). The gene encoding hemagglutinin-esterase (HE), which is . 
commonly found in other CoVs, is absent in the SARS-CoV genome, suggesting that 
this protein is unrelated to SARS-CoV replication (Marra et al” 2003; Rota et al, 
2003). 
Table 1.3 - Features of SARS-CoV genome sequences and subgenomic 
transcripts (Adapted and modified from Chow et al., 2003). 
g/sg niRNA ORF Start-End No. of a.a. No. of Bases Frame 
Thiel et al. Zeiig et al. Marra et al. Rota et al. 
inRNA 1 ORF la ORF la ORF la ORF l a 265-13.398 1 3 , 1 4 9 + 1 
mRNA 1 ORF lb ORF lb ORF lb ORF lb 13,398-21,485 2,628 7,887 + 3 
mRNA 2 S protein S protein S protein S protein 21,492-25,259 1,255 3,768 + 3 
mRNA 3 ORF 3ft XI ORF 3 Xl 25,2(58-26,092 274 825 + 2 
mRNA 3 ORF 3b N/R ORF 4 X2 25,689-26,153 154 465 + 3 
mRNA 4 E protein N/R E protein E protein 26.117-26,347 76 231 + 2 
mRNA 5 M protein M protein M protein M protein 26,398-27,063 221 666 +1 
inRNA 6 ORF 6 N/R ORF 7 X3 27,074-27,265 63 192 + 2 
mRNA 7 ORF 7a X2 ORF 8 X4 27,27;J-27,641 122 369 + 3 
mRNA 7 ORF 7b N/R ORF 9 N / R 27,638-27,772 44 135 + 2 
inRNA 8 ORF 8a X3 ORF 10 N / R 27,779-27,898 39 120 + 2 
mRNA 8 ORF 8b N / R ORF 11. X5 27,864-28,118 84 255 + 3 
mRNA 9 N protein N protein. N protein N protein 28,120-29,388 422 1,269 + 1 




SARS-CoV particles were observed in some SARS patient tissues and 
SARS-CoV-cultivating cells under electron microscopes. The virion is spherical and 
about 60 - 140 nm in diameter. N comprising RNA genome and N protein is located 
in the centre, while the inner core surrounded by outer lipid envelop is made of S, M 
and E proteins. On the virion surface, S protein appearing as complex projections 
with 20 - 40 nm in length is similar to that of other CoVs (Figure 1.2 and 1.3) 
(Ksiazek et al., 2003; Tse et aL, 2004; Zhang et al, 2003). 
S protein z 
RNA genome 
^ ^ ^ ^ N protein 
lOOnm 
Figure 1.2 - Schematic diagram of SARS-CoV. SARS-CoV appearing as a 100 nm 
particle with a corona-like structure is composed of S, E, M and N proteins (Adapted 
and modified from http://www.sarsreference.com/sarsreference.pdf). 
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々 參 趣 知 Figure 1.3 - Morphology of SARS. 
H B R P ^ S S ^ ‘ 务< CoV under electronic microscopy. 
P ^ ^ ^ ^ g j ^ ^ ^ i i P ^ i ^ ^ S � （A) SARS-CoV particles were found in 
W X j f ^ S S t ^ ^ i i k ^ M f ^ d ^ ^ S k dilated cytoplasmic vesicles in lung cells 
S H ^ ^ E S f l l ^ C S S K ^ t * ^ ^ ^ ^ of SARS patients. The arrows indicate 
the particles of the better preserved 
structures. (B) The asterisk arrows 
i f ^ ^ f c � indicate similar viral particles found in 
ST • w-. endoplasmic reticulum (ER) and on the 
& 0.1 nm surface of the cytoplasmic membrane of 
‘ ‘ infected Vero cell respectively. (C) The 
j B B B m i ^ ^ � M 1 .^itx-^, ^ / particles were found in the supernatant of 
Vero cell culture. (D) SARS-CoV with 
an internal helical N-like structure was 
^ ^ B B r 趣 surrounded by club-shaped complex 
W M projections. All bars represent 100 nm 
^ B f ^ ^ ^ ^ ^ ^ (Adapted and modified from Ksiazek 
' m B K t t m \ J H h u t i B et al, 2003 and Tse et al., 2004). 
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1.2.3 Phylogenetic Analysis 
Before SARS outbreak, more than ten identified CoVs were divided into 
three subgroups according to their genome sequences (Horzinek et al” 1999). Protein 
sequence alignment of replicases and structural proteins of SARS-CoV and other 
CoVs showed their identities are approximately between 20 % and 60 %，suggesting 
that they were diverse (Table 1.4) (Rota et al, 2003). From the phylogenetic trees 
constructed by nucleic acid and protein sequences of CoVs, SARS-CoV was located 
between group n and group IH of the CoV family (Figure 1.4) (Eickmaim et aL, 
2003; Ksiazek et al.，2003; Marra et al.’ 2003; Rota et aL, 2003; Spiga et aL, 2003). 
The location further indicated SARS-CoV is not belonged to any subgroup and 
possible to be the first member of a new group of CoV. Nevertheless, some different 
phylogeny analyses demonstrated contradictory - SARS-CoV belongs to a sub-group 
of group II rather than a new group (Gibbs et al., 2004; Gorbalenya et al” 2004; Kim 
et al, 2006). 
Table 1.4 一 Pairwise identities of CoV proteins. Sequences and lengths of SARS-
CoV proteins were compared with that of selected CoVs in the three groups 
including human CoV 229E (HCoV-229E), porcine epidemic diarrhea vims (PEDV), 
transmissible gastroenteritis virus (TGEV)，bovine CoV (BCoV), murine hepatitis 
virus (MHV) and infectious bronchitis virus (IBV) (Adapted and modified from Rota 
et al., 2003). 
Group Virus Pairwise Amino Acid Identity (Percent) . 
3CLPR0 POL HEL S E M N 
G1 HCoV-229E ssis SO? ^ ^ S O ^ 
PEDV 44.4 59.5 61.7 21.7 17.6 31.8 22.6 
TGEV 44.0 59.4 61.2 20.6 22.4 30.0 25.6 
G2 BCoV 48.8 66.3 68.3 27.1 20.0 39.7 31.9 
MHV 49.2 66.5 67.3 26.5 21.1 39.0 33.0 
G3 iBV 41.3 62.5 58.6 21.8 18.4 27.2 24.0 
Virus Predicted Protein Length (aa) 
SARS-CoV 306 932 S51 ^ ^ ^ 
CoV Range 302-307 923-940 506-6001173-1452 76-108 225-262 377-454 
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3CLP- — ) POL 
I L £ Y NW P E D V Y . 1 0 
一 A - x — ( S w ^ 
MHV BCoV ) I V^!；；!^ 
S A R S ^ C O V 
s ( E ( i l p v / ™ ) 
/ HCOV-229E d i 
/ P E D V \ 广 P E D V X 
M SARS-CoV \ ] N / HCOV-229E \ TGEVPRCoV A 
I H秘OV RlCoV J SARS-CoV ( R ® J 
X H E V B C O V J 
Figure 1.4 一 Phylogenetic analysis of CoV proteins. Sequence alignments and 
neighbor-joining trees were generated by comparing 3CLPR0, POL, S, E，M and N 
proteins between SARS-CoV and six of CoVs in the three sub-groups. 
All SARS-CoV proteins were distant from that of other CoVs (Adapted and modified 
from Rota et al.，2003). 
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1.3 S Glycoprotein 
1.3.1 Functional Roles 
S glycoprotein, one of the structural proteins of SARS-CoV, is a TM protein 
passing through the viral membrane. It is approximately 20 - 40 nm in length and 
surrounds the periphery of SARS-CoV surface (Figure 1.2 and 1.3) (Ksiazek et al, 
2003; Tse et al” 2004; Zhang et al., 2003). S plays an important role on mediation of 
viral invasion via receptor binding and membrane fusion. The presence of S protein 
as well as interaction between S protein and receptor are essential for SARS-CoV 
infection (Simmons et al., 2004). Hence, this protein can determine host range, tissue 
tropism, and virulence of SARS-CoV (Gallagher et al., 2001; Kuo et al, 2000). 
Investigation of the protein mediating viral invasion may provide insights for 
the identification of effective methods to prevent the viral infection. For example, 
production of antibody, which can specifically interact with and neutralize S, was 
a possible effective and safety vaccines for therapy (Choy et al., 2004; Lee et al, 
2006; Qin et al, 2006; Sui et al., 2004; Zhou et al, 2006). Besides, other vaccines 
based on S protein such as DNA vaccine inducing T cell and neutralizing antibody 
responses, as well as RNA interference inhibiting S expression were developed (Gao 
et al” 2003b; Li et al, 2005b; Wang et al, 2005; Yang et al, 2004b; Zeng et al, 
2004; Zhang et al.’ 2003; Zhao et al.’ 2004). Other than vaccination, development of 
antibodies recognizing S may help in diagnosis of SARS patients in early stage 
(Chang et al, 2004; Ohnishi et al, 2005). 
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1.3.2 Structure and Functional Domains 
S glycoprotein of SARS-CoV has 1,255 a. a. residues and its theoretical 
molecular weight is 139 kilodalton (kDa) (Ksiazek et al., 2003; Marra et al, 2003; 
Rota et a!., 2003). However, the actual molecular weight is 180 kDa due to the 
presence of at least four glycosylation sites (Krokhin et al., 2003; Ying et al” 2003). 
Alignment results using various CoV S protein sequences revealed that S protein of 
SARS-CoV is only approximately 25 % identical (Table 1.4) (Rota et al, 2003). 
Even though the identity is low; its structure can still be predicted to be a type I TM 
protein and divided into two functional domains, SI and S2, located extracellularly 
near amino (N-) and carboxyl (C-) terminals respectively (Figure 1.5). Their 
functions are binding cellular receptor and mediating fusion between viral and 
cellular membranes respectively. By comparing with other CoVs, SI of SARS-CoV 
is less conserved than S2 (Liu et al•，2004). 
At the N-terminal of SI domain, a signal peptide, which has presumably 
been removed during transport through ER, of approximately 12 a. a. residues was 
identified (Ho et al., 2004a). Amino acid residues 17 - 276 in form of dimer are 
involved in membrane fusion but not receptor-binding (Xiao et al., 2004). Also, a. a. 
residues 318 - 510 were identified as receptor-binding domain (RED) interacting 
with angiotensin-converting enzyme 2 (ACE2) (More details can be found in section 
1.3.3，p. 15) (Li et al, 2003; Wong et al, 2004). 
Between S1 and S2, a proteolytic cleavage site commonly found in most of 
Group II and Group III CoVs is absent in SARS-CoV (Rota et al., 2003). No 
evidence demonstrated that SARS-CoV S protein is cleaved in any stage as well 
(Moore et al., 2004; Simmons et al, 2004; Song et aL，2004; Xiao et al., 2003). 
Absence of the cleavage site causes the exact boundary between S1 and S2 undefined, 
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though a putative site at a. a. residue of 672 is predicted (Xiao et al” 2003). The 
cleavage of SARS-CoV is unnecessary for viral infection but enhances membrane 
fusion (Bosch et al, 2004; Follis et al； 2006; Simmons et al., 2004; Song et al” 
2004; Xiao et al.’ 2003). 
Presence of fusion peptide (FP), a short peptide upstream of HRl, in SARS-
CoV S2 domain is predicted as other Co Vs. This hydrophobic peptide is rich in 
alanine, glycine and phenylalanine residues, and possesses a proline residue. During 
viral entry, FP exposes and associates with host cell membrane leading to membrane 
fusion. The predicted FP location is approximately a. a. residues 858 一 886 (Bosch 
et al. 2004; Ingallinella et al, 2004; Petit et al\ Supekar et al. 2004). Nonetheless, 
a. a. residues 770 - 788 inserting into the lipid membrane were demonstrated (Sainz 
et al., 2005)，so the exact location of FP in SARS-CoV remains to be determined. 
Amino acid residues 896 一 972 and 1142- 1188 are Heptad Repeat 1 (HRl) 
and 2 (HR2) respectively, which play important roles for membrane spinning (More 
details can be found in section 1.3.4, p. 17) (Bosch et al, 2004; Xu et al” 2004b; Zhu 
et cd., 2004). They are helical and themselves assemble into a coiled coil structure 
(Ingallinella et al, 2004; Tripet et al, 2003). The HRl connects FP and HR2 while 
the HR2 association in native pre-fusogenic stage leads to trimerization of S protein 
(More details can be found in section 1.3.4, p. 17) (Hakansson-McReynolds et al.’ 
2006). 
At S2 C-terminal, regions located inside the viral membrane and inner core 
compartment are named TM domain and cytoplasmic tail respectively. TM is critical 
for viral infection and stabilization of S protein trimerization (Broer et al, 2006; 









o m i m ^ ^ ^ ^ ^ ^ ^ m i m m i g g i ^ m i ^ i n i ^ hcov-oc43 
H I Z I I ^ ^ Z ^ ^ H H H H ^ b H I H H H H H ^ H I l MHV 
• 
[ | | | | | | | | | | m m | | [ | H | m InAuenza-HA 
T 
• i ^ m m m ^ ^ B i B i i i ] ] ] ^ ^ ； ^ Hiv-gpi6o 
• Signal peptide • S2 • HR2 
• S1 • Fusion peptide • Transmembrane domain 
I I Receptor binding • HR1 • Cytoplasmic tail 
Figure 1.5 - Structural features of selected CoV S proteins (Adapted and 
modified from Hofmann et al., 2004c). 
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1.3.3 Interacting Partners 
ACE2, a 120 kDa type I (C-terminus intracellular) integral membrane protein 
mainly expressed in heart, kidney and testes, lung and intestine, was identified as 
a functional receptor of SARS-CoV (Douglas et al, 2004; Hofmann et al, 2004a; Li 
et al.’ 2003; Tikellis et al.’ 2003; Wang et al, 2004). SARS-CoV infection and 
replication were detected in ACE2-transfected 293T cells, which are originally 
SARS-CoV non-susceptible cells (Figure 1.6). Also, viral infection on VeroE6 cells, 
that were SARS-CoV susceptible cells, was blocked by anti-ACE2 antibody 
(Figure 1.7). ACE2 is a zinc metallopeptidase cleaving one a. a. from the C-terminal 
of substrates and is important for regulation of cardiac function (Averill et al., 2003; 
Crackower et al., 2002; Donoghue et al, 2000; Tipnis et al. 2000; Zisman et al, 
2003). Its peptidase domain is proved to be assembled with a. a. residues of 
318 - 510 of SARS-CoV S protein (Babcock et al.’ 2004; Li et al.，2005a; Towler 
et al., 2004; Wong et al, 2004; Xiao et al., 2003). 
On the other hand, interactions between S glycoprotein and two kinds of TM 
C-type (calcium dependent) lectin, dendritic cell-specific ICAM-grabbing 
non-integrin (DC-SIGN) and its homologues DC-SIGN-related protein (DC-SIGNR / 
CD209L), were demonstrated (Marzi et al•’ 2004; Jeffers et al, 2004). DC-SIGN is 
expressed on DC surface and some types of macrophages while DC-SIGNR is 
located on sinusoidal endothelial cells and placental macrophages (Bashirova et al., 
2001; Geijtenbeek et al, 2000; Soilleux et al, 2001). The major physiological role of 
DC-SIGN is to interact with conserved molecules of some pathogens and then 
initiates immune responses against the pathogens (van Kooyk et al” 2003). They are 
however served as attachment factors, enhancing the interaction between SARS-CoV 
S protein and other interacting partners, rather than functional receptors (Marzi et al, 
15 
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2004). In HIV-infected cells, they act as attachment factors associating with a range 
of viral proteins including the envelope protein (Alvarez et al, 2002; Gardner et al, 
2003; Geijtenbeek et al., 2000; Klimstra et al., 2003; Lozach et al, 2003). 
Dilution series (10"^) 
1 2 3 4 5 6 7 8 9 
M o c k D a y o c s a a 
Day E I 3 C I 3 I ^ 3 H 
1 2 3 4 5 6 7 8 9 
Day 0 HHHIIIIHI 
Day 2 
Figure 1.6 - SARS-CoV infection in SARS-CoV non-susceptible ACE2-
transfected cell line. The presence of viral RNA in 293T cells medium in various 
dilutions was detected by RT-PCR. RNA was detected in 293T cells with 
ACE2-transfection but not mock-transfection control (Adapted and modified from 
Li et al” 2003). 
難•誦 
隱纖 
Figure 1.7 - Blockage of SARS-CoV infection by anti-ACE2 antibody. 
(A) Syncytia formation was determined between S protein- and ACE2-expressing 
293T cells. (B) The syncytia formation was inhibited by anti-ACE2 antibody 
(Adapted and modified from Li et al., 2003). 
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1.3.4 Viral Entry Mechanism 
S glycoprotein binding to functional receptor on the host cell surface is the 
initial step of viral entry. Afterwards, SARS-CoV is predicted to enter host cells by 
two pathways as other enveloped viruses (Figure 1.8) (Eckert et al., 2001; Hofmann 
et al, 2004a; Smith et al, 2004; Yeung et al., 2006). In the pH-dependent pathway, 
receptor binding causes internalization of virion into endosomes by endocytosis. 
In the presence of hydrogen ion pump on the membrane, acidification of endosomal 
compartment induces conformational change in the S protein. With regards to the 
pH-independent pathway, receptor-binding directly triggers change in S protein 
conformation. 
In some cases, viral infection can be inhibited by ammonium chloride 
(NH4CI), which neutralizes the acidic environment of endosome (Hofmann et aL, 
2004b; Nie et al, 2004; Simmons et al., 2004; Yang et al.，2004a), suggesting that 
SARS-CoV pathogenesis is a pH-dependent endocytotic process. Viral entry via 
membrane fusion at the cell surface was also observed by microscopy (Zhang et al., 









H Spike glycoprotein trimer 0 Membrane protein O Small envelope protein Nucleocapsid 
Figure 1.8 一 Schematic diagram of two putative pathways triggering 
conformational change in SARS-CoV S protein. The left is the pH-independent 
pathway that receptor-binding directly triggers change in S protein conformation. 
Viral and plasma membranes are fused and hence N is released to cytoplasm. 
The right is the pH-dependent pathway that receptor-binding induces virion is 
up taken into the endosome. Acidification of endosomal compartment induces 
the conformational alteration leading to membrane fusion. The acidification can be 
inhibited by NH4CI or bafilomycin A (BAF) and thus blocks the viral entry (Adapted 
and modified from Hofmann et al., 2004c). 
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After SI dissociation, FP covered in native pre-fusogenic stage exposes and 
inserts to host cell membrane surface (Figure 1.9). Next, in fusion active state, HR2 
folds back onto HRl leading to a six-helix bundle structure (trimer of dimers) 
formation. HRl associates into a central trimeric coiled coil structure and HR2 are in 
anti-parallel orientation, thereby bringing the host cell membrane and SARS-CoV 
TM domain into close contact, and hence promoting membrane fusion (Duquerroy 
et al, 2005). Afterwards, viral N can be transferred to host cell cytoplasm for viral 
replication (Hofmann et al, 2004c). 
I Cellular membrane Transfer of viral nucleocapsid 
“I：：： J^^F^^ 
^^m^ 3 
Viral membrane ^ 
1 
Figure 1.9 一 Schematic diagram of the three states of SARS-CoV S protein 
during viral entry. (1) S protein in native pre-fusogenic stage does not bind to any 
receptor. (2) In intermediate state, after binding, S1 domain dissociates to expose FP 
which inserts to host cell membrane. (3) The S2 domain in fusion active state 
collapses to draw the viral and host cell membranes together leading to membrane 
fusion and hence transfer of viral N (Adapted and modified from Tripet et al., 2004). 
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1.4 Aim of Study 
1.4.1 Mismatch ofSAR S-CoV Tissue Tropism and Tissue Distribution of ACE2 
Tissues and cell lines expressing functional receptors are theoretically 
susceptible to SARS-CoV, and vice versa. SARS-CoV replication leads to the 
presence of viral RNA, proteins and virions in the infected tissues of SARS patients. 
The comparison results indicated the general pattern of ACE2 expression roughly 
agrees with SARS-CoV tropism. For instance, lung and intestine expressing ACE2 
were the major infected organs where viral RNA, proteins and particles were 
identified (Table 1.5) (Chow et al, 2004; Ding et al., 2004; Hamming et al.，2004; 
Harmer et al” 2002; Leung et al, 2003; To et al., 2004a; To et al., 2004b; Tse et al., 
2003). 
On the contrary, discrepancies were appeared since some tissues highly 
expressing ACE2 were SARS-CoV' insusceptible, while SARS-CoV was found in 
some tissues without ACE2 (Table 1.5) (Chau et al., 2004; Ding et al., 2004; 
Hamming et al., 2004; Harmer et al, 2002; To et al, 2004a; To et al.’ 2004b). 
No virus could be detected in heart as well as endothelium of most organs that are 
highly expressing ACE2, whereas viral RNA and proteins were presented in 
hepatocytes without ACE2. 
Similar results were determined during studying susceptibilities of various 
cell lines. SARS-CoV was replicated in VeroE6 cells expressing ACE2 but not in 
HepG2, HeLa, MDCK and LLC-MK2 without ACE2 (Chan et al” 2003; Ng et al., 
2003a; Ng et al., 2003b). Nonetheless, a few human colorectal adenocarcinoma cell 
lines expressing ACE2，including HCT-116, DLD-1, HT-29, SW-480, LS-180 and 
- 等 
SW-620, were non-permissive to viral infection (Table 1.5) (Chan et al, 2004a). 
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Table 1.5 - Comparison between selected SARS-CoV susceptible tissues and 
tissue distribution of ACE2 (Chau et al, 2004; Chow et al, 2004; Ding et al, 2004; 
Hamming et al, 2004; Harmer et al., 2002; Leung et al.’ 2003; To et aL, 2004a; 
To et al.，2004b; Tse et aL, 2004). 
SARS-CoV SARS-CoV 
susceptible cells insusceptible cells 
Lung Kidney 
- Alveolar epithelia - Glomerular viscerals 
- P n e u m o c y t e s - Parietal epithelial cells 





- Surface enterocytes 
- E p i t h e l i a l cells 
- G a s t r i c parietal cells Heart 
Kidney Thyroid 
rj,. - Distal convoluted tubules Oesophagus 
1 issues ® 
with ACE2 - Epithelial cells of distal 
convoluted renal tubules Spleen 
- C e r e b r a l neurons 
- Adrenal cortical cells Bone marrow 
- M e d u l l a r y cells 
Ovary 
Parathyroid and pituitary 
Uterus 










- K u p f f e r cells 
- Sinusoidal endothelia 
21 
INTRODUCTION 
1.4.2 Presence of Other Interacting Partner(s) 
Mismatch between SARS-CoV tissue tropism and tissue distribution of 
ACE2 indicates the presence of ACE2 alone is insufficient for viral invasion. Other 
attachment factor(s) or co-receptor(s) enhancing the viral invasion ability may hence 
be present. In susceptible cells without ACE2, other functional receptor(s) involved 
in viral infection is possible to be existed as well. Collectively, we believe that other 
unidentified interacting partner(s) involved in SARS pathogenesis remains to be 
discovered. 
1.4.3 Significance of the Study 
Identification of interacting partners involved in SARS pathogenesis may be 
beneficial to investigate SARS-CoV entry mechanism, which is still remaining 
unclear. The results of this project may also provide insights into the investigation of 
SARS pathogenesis. Since RED of S presumably is the most effective target epitope, 
construction of antibody binding to new RBD may block the interaction between 
virus and receptor. Last but not least, investigation of interactions between S and 
its interacting partners in other organisms may provide information of origins of 
SARS-CoV in order to have a better control of the future SARS outbreak. 
22 
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Plasmid Construction 
2.1 Fragment Design 
2.1.1 Functional Domain Analysis 
SI and S2, the two functional domains of the SARS-CoV S glycoprotein 
responsible for binding cellular receptor and mediating membrane fusion 
respectively, were selected for expression (Figure 2.1). Since the signal peptide in SI 
and the TM domain in S2 were hydrophobic, truncated SI (a. a. residues 13 - 672) 
and S2 (a. a. residues 680 - 1192) were expressed (Broer et al.’ 2006; Ho et al., 
2004a; Li et al” 2003; Xiao et al, 2003). 
The expression levels and solubility of SI and S2 may be low because of 
their high molecular weights (74 kDa and 56 kDa respectively). Another four 
domains with lower molecular weights were consequently selected for expression in 
parallel (Figure 2.1). One of these domains is the RED (a. a. residues 318 - 510), 
which can be used to identify other interacting partner(s) other than ACE2, as well as 
act as a positive control. Another selected domain is a combination of HRl and HR2. 
Finally, two fragments located at the upstream region of RED and between RED and 
HRl were chosen. 
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2.1.2 Secondary Structure and Burial Region Predictions 
Secondary structure and burial regions of S protein were predicted by 
an online database named "Jpred" (http://www.compbio.dundee.ac.uk/~www-jpred/) 
(Figure 2.2). The S protein a. a. sequence was also analysed by other algorithms 




html), PORTER (http://distill.ucd.ie/porter/) to confirm the results. Three fragments 
(a. a. residues 15 - 317，587 - 826 and 903 - 1187) were subsequently selected 
(Figure 2.1). Their N- and C-terminals contain random coils and are hydrophilic. 
S1 (13-672) ] ( ~ S2 (680-1192) 
15-317 I 318-510 I 587-826"^ | 903-1187 
Figure 2.1 - Schematic diagram of selected fragments. Orange, green and purple 
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MATERIALS AND METHODS 
2.2 Vector Amplification 
2.2.1 E. coli Strain DH5a Competent Cell Preparation 
Glycerol stock of E. coli strain DH5a was streaked on a Luria-Bertani (LB) 
plate (GE Healthcare) and incubated at 37 °C overnight. A single colony was 
inoculated to 5 mL of LB medium (GE Healthcare) and shaken at 37 °C overnight 
at 250 revolutions per minute (r.p.m.). The inoculum was transferred to 500 mL of 
LB medium, followed by shaking until an optical density at 600 nm (OD^oo) between 
0.4 — 0.6 was reached. 
Harvested cell pellet was chilled on ice for 15 minutes in 167 mL of 
RFl solution (pH 5.8) [100 mM rubidium chloride (RbCl), 50 mM manganese 
chloride, 30 mM potassium acetate, 10 mM calcium chloride (CaCy and 25 mL of 
glycerol]. The harvesting and chilling procedures were repeated except RFl solution 
was replaced by 40 mL of RF2 solution (pH 6.8) [lOmM 3-(N-morpholino) 
propanesulfonic acid, 10 mM RbCl, 75 mM CaCl: and 6 mL of glycerol]. Aliquots 
of competent cells were stored at -80 °C. 
2.2.2 Transformation of E. coli 
One microgram of pGEX-6P-l (GE Healthcare), pET-28a (Novagen), 
pRHisMBP or pPICZa-A (Invitrogen) was added to 200 [iL of thawed competent 
cells. After staying on ice for 15 minutes, cells were heat shocked at 42 °C for 
90 seconds and then stayed on ice for five minutes. Next, 800 |LIL of LB medium was 
added and shaken at 37 °C for one hour at 250 r.p.m. for recovery. Then, 200 |iL of 
them containing pGEX-6P-l and pRHisMBP were spread to LB plates with 
100 |Lig/mL of ampicillin (GE Healthcare) while that containing pET-28a and 
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pPICZa-A were spread to the plates with 30 ^ig/mL of kanamycin (Invitrogen) and 
25 |ig/mL of zeocin (Invitrogen) respectively. The plates were incubated at 37 °C 
overnight. 
2.2,3 Small-scale Vector Amplification 
Vector amplification was performed by "Rapid Miniprep System (250)" 
(Marlign biosciences). For each vector, a transformant on the plate was inoculated in 
6 mL of LB medium with corresponding antibiotic and then shaken at 37 °C 
overnight at 250 r.p.m. Each harvested cell pellet was resuspended in 500 |iL of 
Cell Suspension Buffer Gl , followed by mixing with 500 (aL of Cell Lysis Solution 
G2. After staying for five minutes, 350 fiL of Neutralization Buffer M3 was mixed 
and centrifuged at 12,000 g for ten minutes. Supernatant was transferred to a column 
and centrifuged at 12,000 g for two minutes, followed by 800 i^L of Wash Buffer G4. 
The vectors were eluted by 50 |iL of distilled water (H2O). 
OD260 and OD280 of samples diluted in 100-folds were measured by using 
distilled H2O as blank. The concentrations were calculated as follows: 
"Concentration (ng / |iL) = OD260 x 100 (dilution fold) x 50" while the purities were 
calculated by OD260 丨 ODjgo ratio. 
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2.3 Cloning of DNA Fragments into Various Vectors 
2,3.1 Primer Design 
All primers were designed by "GeneTool Lite" (http://www.DoubleTwist. 
com) using SARS-CoV strain CUHK-SulO as template (Tsui et al., 2003). Their 
lengths and melting temperatures are approximately 20 base pair (bp) and 54°C 
respectively. Nucleotide sequence "TTA" ("TAA" in reverse and complement) 
encoding a stop codon for translation termination was added in each reverse primer 
involved in cloning into pGEX-6P-l and pRHisMBP. Moreover, a cap sequence 
"TAGGGC" and a restriction site were provided at the beginning of each primer for 
restriction enzyme binding and digestion respectively (Table 2.1). 
Table 2.1 - Features of S protein fragments. 
• J Range of Range of T r a. a. residues of , � • i � . Lengths of 广 ^ nucleotides in nucleotides in , protein fragments 丄, ,丄 � ， 丄• nucleotide sequence the complete genome the S glycoprotein ^ 
~ 1 3 - 6 7 2 ( S I ) ~ 21513-23492 3 7 - 2 0 1 6 1980 
680-1192 (S2) 23516-25052 2038-3576 1539 
15-317 21521 -22427 4 3 - 9 5 1 909 
318-510 22428-23006 9 5 2 - 1530 579 
587-826 23235-23954 1759-2478 720 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MATERIALS AND METHODS 
2.3.2 DNA Amplification 
DNA for pGEX-Sl, pGEX-S2 and pGEX-(5 87-826) construction were 
amplified by polymerase chain reaction (PGR) using complementary 
deoxyribonucleic acid (cDNA) of CUHK-SulO as template. 50 |iL of each PGR 
mixture containing 0.2 mM deoxynucleoside triphosphate (dNTP), one unit of pfu 
polymerase and 1 X of pfu polymerase buffer (Promega), 2 i^M of corresponding 
forward and reverse primers (Proligo), and 1 ng of cDNA were prepared. 
PGR mixture without template was prepared in parallel as a negative control. 
The cycling conditions for PGR were as follows: 94 °C for three minutes, 35 cycles 
of 9 4 � C for 36 seconds, 55 °C for 45 seconds, 72 °C for five minutes, and 72 °C for 
ten minutes as the final extension. The PGR was performed in DNA engine 
thermocycler (MJ Research) and amplified PGR products were used as templates to 
construct other plasmids. 
2JJ DNA Purification 
The PGR products were subjected to Tris(hydroxymethyl)aminomethane-
acetate-ethylenediaminetetraacetic acid (TAE) agarose gel electrophoresis. 50 |iL of 
each PGR mixture mixing with 10 |aL of 6 X DNA loading dye [0.25 % (w/v) 
bromophenol blue, 0.25 % (w/v) xylene cyanol FF and 30 % (v/v) glycerol] was 
loaded to wells of the gel [40 mM Tris(hydroxymethyl)aminomethane-
Hydrochloride (Tris-HCl), 20 mM acetic acid, 1 mM ethylenediaminetetraacetic acid 
(EDTA) (pH 8.0)，0.005 % (v/v) ethidium bromide and 1 % - 1.5 % (w/v) agarose)]. 
2 |ig of 100 bp ladder DNA marker or GeneRuler 1 Kb DNA ladder (Fermentas) was 
loaded in parallel to determine sizes of the PGR products. After electrophoresis, 
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the PCR products in the gel were visualized under UV light at an emission 
wavelength of 340 nm. 
The regions of the gels containing the desired PCR products with expected 
sizes were isolated and extracted by "QIAQuick Gel Extraction Kit" (Qiagen). 
Each isolated gel slice was dissolved in 900 fiL of buffer QC and then mixed with 
300 |LIL of isopropanol. The mixture was transferred to a QIAquick Spin Column and 
centrifuged at 12,000 g for two minutes, followed by 750 |aL of buffer PE. The PCR 
products were eluted by adding 30 |iL of sterile H2O at 70 °C and centrifuging at 
12,000 g for three minutes. 
2.3.4 Restriction Enzyme Digestion，Ligation and Transformation 
Each mixture containing 28 |JL of each purified PCR product, 2 X of 
One-phor-All buffer (GE Healthcare), and restriction enzymes (2 |j.L each), was 
prepared. Single-cut vector control and uncut vector control were prepared in parallel. 
The mixtures were digested at 37 °C for five hours and then heat inactivated at 85 °C 
for 15 minutes. Afterwards, purification of the restricted PCR products and vectors 
were performed as mentioned in section 2.3.2 (p.35). 
Ten microliters of each mixture containing 6 - 7.5 |iL of the digested PCR 
products, 1 - 2.5 i^L of linearized vectors, 200 U of T4 DNA ligase and 1 X T4 DNA 
ligase buffer (New England BioLabs) were prepared. The ratio of the amount of PCR 
product and vector was approximately three to one. The mixture was ligated at 4 °C 
overnight and then transformed into DH5a competent cells. 
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2.3,5 Colony PCR 
Six to thirty colonies were streaked to another LB plate with corresponding 
antibiotic and then transferred to 5 |JL of PCR mixture containing 10 mM Tris-HCl 
(pH 9.0)，50 mM potassium chloride (KCl), 1.25 mM magnesium chloride (MgCy, 
0.2 mM dNTP, 2 |JM corresponding vector forward and reverse primers and 0.25 U 
of Taq polymerase. PCR was performed under the following cycling profile: 94 °C 
for three minutes, 35 cycles of 94 °C for 36 seconds, 55 °C for 45 seconds，72 °C for 
two minutes, and 72 °C for ten minutes for the final extension. The presence of PCR 
products was determined by TAE agarose gel electrophoresis. For each construct, 

























































































































































































































































































































































































































































































































































































































































































































MATERIALS AND METHODS 
2.4.2 DNA Amplification and Purification for DNA Sequence Analysis 
Twenty microliters of each PGR mixture containing 2 |iL of BigDye 
Terminator v3.1 Cycle Sequencing RR-100 (Applied Biosystems), 0.75 X of BigDye 
Terminator vl.l，v3.1 Sequencing Buffer (Applied Biosystems), 0.5 [ M vector or 
gene-specific primer, and 200 ng of plasmid was prepared. The primers for DNA 
sequence analysis could be found in table 2.4. The cycling conditions for PGR were 
as follows: 96 °C for three minutes, 26 cycles of 96 °C for ten seconds, 55 °C for 
five seconds and 60 °C for four minutes. 
Each PGR product mixing with 5 |iL of 125 mM EDTA and 60 |iL of 99.9 % 
(v/v) ethanol (EtOH) was centrifuged at 1,500 g for 30 minutes at 4 °C. Supernatant 
was removed by centrifugation at 50 g for one minute at 4 � C . Each pellet 
resuspended in 60 \xL of 70 % EtOH was further centrifuged at 1,500 g for 
15 minutes at 4 °C. After repeating the centrifugation, each pellet was resuspended in 
15 |j,L of Hi-Di Formamide (Applied Biosystems) and denatured at 9 5 � C for two 
minutes. 
39 
MATERIALS AND METHODS 
Table 2.4 - Primers for recombinant plasmid sequence analysis. 
Name of plasmid Name of primer 
pGEX-Sl pGEX-F，37BF，38BF, 39BF，pGEX-R, 37AR, 38AR, 39AR 
pGEX-S2 pGEX-F, 41AF, 42AF, pGEX-R, 40BR，41 BR 
pGEX-(15-317) pGEX-F, 37BF, pGEX-R, 37AR 
pGEX-(318-510) pGEX-F, pGEX-R 
pGEX-(587-826) pGEX-F，40BF, pGEX-R, 39BR 
pGEX-(903-l 187) pGEX-F, 42AF，pGEX-R, 41BR 
pET-Sl T7-P, 37BF, 38BF，39BF, T7-T，37AR, 38AR, 39AR 
pET-S2 T7-P，41AF, 42AF, T7-T, 40BR, 41 BR 
pET-(15-317) T7-P，37BF, T7-T, 37AR 
pET-(318-510) T7-P, T7-T 
pET-(587-826) T7-P, 40BF，T7-T，39BR 
pET-(903-1187) T7-P, 42AF, T7-T，41BR 
pRHisMBP-Sl T7-P, 37BF, 38BF，39BF, T7-T, 37AR, 38AR, 39AR 
pRHisMBP-S2 T7-P, 41AF, 42AF, T7-T, 40BR，41 BR 
pRHisMBP-(15-317) T7-P, 37BF, T7-T, 37AR 
pRHisMBP-(318-510) T7-P，T7-T 
pRHisMBP-(587-826) T7-P, 40BF, T7-T, 39BR 
pRHisMBP-(903-1187) T7-P, 42AF, T7-T，41BR 
pPICZa-Sl a-F, 37BF, 38BF, 39BF, AOXl-K, 37AR, 38AR, 39AR 
pPICZa-S2 a-F, 41AF, 42AF, AOXl-K, 40BR，41BR 
pPICZa-(15-317) a-F, 37BF,^0^7-R, 37AR 
pPICZa-(318-510) a-F, AOXl-R 
pPICZa-(587-826) a-F, 40BF, AOX!-R, 39BR 
pPICZa-(903-1187) a-F, 42AF, AOXJ-R, 41BR 
2.4,3 Sequence Detection and Result Analysis 
The sequencing products were subsequently analysed by the ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems). The results were recorded by "ABI 
PRISM 3100/3100-Avant Data Collection", generated in chromatogram format and 
visualized by "Chromas Version 2.13” (http://www.mb.mahidol.ac.th/pub/chromas/ 
chromas.htm). The nucleotide sequences were then analysed by the "nucleotide-
nucleotide BLAST" under the "Basic Local Alignment Search Tool" (BLAST) 
developed by the Nation Center for Biotechnology Information (http://www.ncbi.nlm. 
nih.gov/BLAST/) for alignment. . 
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Protein Expression, Purification 
and Analysis 
3.1 Protein Expression in E. coli 
3.1.1 Molecular Weight and pi Predictions 
The molecular weights (M. W.) and pi of S protein fragments with various 
tags were predicted by "Compute pi / Mw tool" (http://au.expasy.org/tools/pi_tool. 
html) in order to determine the integrity of expressed proteins and the influence of 
buffer pH on protein solubility. 
3.1.2 Glycerol Stock Preparation 
One transformant containing each constructed plasmid was inoculated in 
0.5 mL of LB medium with corresponding antibiotic. Each inoculum was mixed with 
0.5 mL of sterile glycerol and stored at -80 °C. 
3.1.3 Protein Expression Induction 
One microliter of Rosetta 2’ C41，Origami (kindly provided by Professor 
W. N. Au.) and BL21 glycerol stock carrying plasmid was inoculated in LB medium 
with corresponding antibiotic and then shaken at 37 °C overnight at 250 r.p.m. 
The inoculum was transferred to LB medium with corresponding antibiotic so that 
the final overnight culture percentage was 1 % and further shaken at 3 7 � C at 
250 r.p.m. until mid-log phase (OD^QO = 0.4 一 0.6) was reached. Iso-propylthio-p-D-
galactopyranoside (IPTG) (Shanghai Shenergy Biocolor Bioscience & Technology 
Company) was added so that its final concentration was 0.2 mM. The cultures were 
shaken at 250 r.p.m. for 3 - 1 6 hours. 
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3.L4 Protein Extraction 
Cells expressing Glutathione S-Transferase (GST) fusion protein were 
harvested and cell pellet was resuspended in GST buffer [10 mM Tris-HCl (pH 7.4)， 
300 mM sodium chloride (NaCl), 0.5 mM EDTA, 2 mM dithiothreitol (DTT) and 
0.2 mM phenylmethylsulfonyl fluoride (PMSF)] or phosphate buffer saline (PBS) 
with 2 mM DTT and 0.2 mM PMSF. Addictives including 100 mM DTT, 1 M urea 
and 1 % (v/v) triton X-100 (Sigma) were individually added to GST buffer during 
optimization. On the other hand, cell pellet expressing His fusion proteins or 
His-Mannose binding protein (MBP) fusion protein was resuspended in His buffer 
[10 mM Tris-HCl (pH 7.4), 250 mM NaCl, and 0.2 mM PMSF] with 5 mM 
imidazole (Sigma). 
The resuspended cells were disrupted by using the Sonoplus ultrasonic 
homogenizer system (Bandeln). The sonication processes were performed on ice to 
prevent over-heating. 10 |JL of lysate was saved as total lysate for analysis. 
The lysate left was centrifuged at 48,000 g for 30 minutes at 4 °C and supernatant 
containing soluble fusion protein was stored at 4 °C. 10 |iL of supernatant was saved 
for subsequent analysis. 
3.1.5 Affinity Chromatography 
Five milliliters of supernatant containing soluble GST fusion protein was 
added to 100 \iL of bed volume of equilibrated glutathione sepharose 
(GE Healthcare). The mixture in 1.5 mL of microcentrifuge tube was gently shaken 
at 4 °C for one hour so that the GST fusion protein was immobilized on 
the glutathione sepharose. After centrifugation, 10 [xL of flow through was saved for 
analysis while the remaining was discarded. The glutathione sepharose was washed 
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five times with 1 mL each of buffer to remove non-specifically bound proteins. 
The immobilized GST fusion protein was finally eluted three times with 100 \xL each 
of buffer containing 10 mM reduced glutathione (Calbiochem). Eluents were mixed 
and stored at 4 °C. 
For His fusion proteins as well as His-MBP fusion proteins, the procedures 
were same as that for GST fusion protein except His-binding resin (Merck) were 
used instead of glutathione sepharose. After charging of His-binding resin by 50 mM 
nickel sulphate (NiS04), His buffers with 5 mM, 50 mM and 500 mM imidazole 
were used to equilibrate the resin, wash and elute the proteins respectively. 
3.1.6 Removal of GroEL 
To remove GroEL by adenosine triphosphate (ATP), 150 mL of BL21 
expressing GST-Sl at 16 °C overnight was lyzed in 5 mL of GST buffer. 
After extraction, supernatant was added to 5 mL of 2 X ATP buffer (pH 7.4) 
(GST buffer with 20 mM ATP disodium salt (Sigma), 40 mM MgCl� and 100 mM 
KCl). The mixture was gently shaken at 4 °C, 25 °C or 37 °C overnight. Then, 
100 |iL of bed volume of equilibrated glutathione sepharose was added and gently 
shaken for one hour. After immobilization, the glutathione sepharose was washed 
five times with 1 mL each of 1 X ATP buffer (pH 7.4). GST-Sl was finally eluted 
three times with 50 |aL of 1 X ATP buffer with 10 mM reduced glutathione. Eluents 
were mixed and stored at 4 °C. 
On the other hand, to remove GroEL by urea, 200 mL of BL21 expressing 
GST-Sl at 16 °C overnight was lyzed in 12 mL of PBS. After extraction, supernatant 
with soluble GST-Sl was added to 450 |iL of bed volume of equilibrated glutathione 
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sepharose. The mixture was gently shaken at 4 � C for one hour and then washed five 
times by 1 mL each of PBS. 50 |iL of the glutathione sepharose was gently shaken in 
1 mL of PBS with 0 M, 0.5 M, 1 M, 1.25 M, 1.5 M, 1.75 M，2 M，2.25 M or 2.5 M 
urea at 4 � C overnight. After washing three times by 1 mL each of PBS with various 
urea concentrations followed by PBS without urea, the immobilized GST-Sl samples 
were finally eluted three times with 100 |LIL each of PBS with 10 mM reduced 
glutathione. Eluents were mixed and stored at 4 °C. 
3.1,7 Protein Solubilization and Refolding 
His-(15-317), His-(318-510), His-(587-826), His-(903-1187) were 
individually expressed in 50 mL of BL21 cells at 25 °C for four hours and then 
extracted. Afterwards, each insoluble cell pellet was resuspended in 5 mL of 
solubilization buffer [His buffer with 6 M guanidine hydrochloride (guHCl)] with 
5 mM imidazole, followed by centrifugation at 48,000 g for 30 minutes at 4 °C. Each 
His-fusion protein in the supernatant was immobilized on 500 |JL of His-binding 
resin, washed five times by 1 mL each of solubilization buffer with 50 mM imidazole 
and eluted three times by 150 |iL of solubilization buffer with 500 mM imidazole. 
The unfolded recombinant proteins were refolded in buffers with various 
conditions by rapid dilution. In brief, 2 |a,L of each unfolded His-fusion protein in 
a concentration of about 0.5 |j.g/|iL was added to 190 |iL of refolding buffers and 
mixed immediately. The procedures were repeated four times so that the final 
volume was 200 |LIL. After staying at 4 °C overnight, the mixture was centrifuged at 
14,000 g for 15 minutes at 4 � C in order to remove insoluble protein and the 
supernatant was then analysed by SDS-PAGE. After primary screening, the refolding 
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condition with the highest refolding yield was chosen for further secondary and 
tertiary screenings. The compositions of refolding buffers were listed in table 3.1. 
Table 3.1 - Compositions of refolding buffers. All buffers for primary and 
secondary screenings contain 1 mM EDTA. L-arginine, reduced glutathione (GSH), 
oxidized glutathione (GSSG)，polyethylene glycol (PEG), MgCl:，Cad，and EDTA 
were addictives of buffers. 
N o .卯 - H C l ( M ) L-arginine (mM) GSH (mM) GSSGCmMF" 
0 0 2 0.2 
2 0 0.4 2 0.4 
3 0 0.8 1 1 
Primary 4 0.5 0 2 0.4 
screening 5 0.5 0.4 1 1 
6 0.5 0.8 2 0.2 
7 1 0 1 1 
8 1 0.4 2 0.2 
9 1 0.8 I 2 I 0.4 
PEG ( _ 
2 The best Pq 
Secondary ^ refolding .QQ 
screening ^ condition in j^q 
5 primary 200 
6 screening 250 
"TJO" MgCl./CaCl, (mM) I EDTA (mM) 
~ 1 _ , + 0 / 0 1 
2 The best 2 / 2 0 
Tertiary . refolding 4 / 4 q 
screening condition in . . . q 
5 secondary q 
6 screening l o / l O 0 
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3.2 Protein Expression in P. pastoris 
3.2.1 Large-scale Plasmid Amplification 
Plasmid amplification was performed by "HiSpeed Plamid Midi Kit" 
(Qiagen). 1 i^L of DH5a glycerol stock containing the plasmid was inoculated in 
200 mL of LB medium with 25 |Lig/mL of zeocin and shaken at 37 °C overnight at 
250 r.p.m. Harvested bacterial pellet was resuspended in 7 mL of Buffer PI, 
followed by 7 mL of Buffer P2. After incubating for five minutes, 7 mL of Buffer P3 
was added and the mixture was poured immediately into the barrel of the QIAfilter 
Cartridge followed by ten minutes incubation. In the meanwhile, HiSpeed Midi Tip 
was equilibrated in 4 mL of Buffer QBT. Afterwards, the cap from the QIAfilter 
Cartridge was removed and a plunger was gently inserted so that the cleared cell 
lysate passed through the resin in the equilibrated HiSpeed Tip. The HiSpeed Tip 
was washed by 20 mL of Buffer QC and the plasmid was eluted by 5 mL of Buffer 
QF. 
The eluent mixing with 3.5 mL of isopropanol was incubated for five minutes 
for DNA precipitation. The mixture was transferred into a 20 mL syringe, in which 
the outlet nozzle was attached to the QIAprecipitator Midi Module, and then filtered 
through the QIAprecipitator using constant pressure so that the plasmid was trapped. 
Afterwards, the QIAprecipitator was removed from the 20 mL syringe and 
the plunger was pulled out. After re-attaching the QIAprecipitator, the plasmid was 
washed by 2 mL of 70 % EtOH by inserting and pressing the plunger using constant 
pressure. Finally, the QIAprecipitator was attached onto a new 5 mL syringe and 
then the plasmid was eluted by 1 mL of distilled H2O. Plasmid concentration and 
purity were measured. 
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3.2.2 Restriction Enzyme Digestion and Ethanol Precipitation 
A restriction mixture containing 25 |ig of plasmid, 6 |JL of Sad and 1 X of 
the buffer L (GE Healthcare) was incubated at 37 °C for five hours, followed by heat 
inactivation at 85 °C for 15 minutes. The mixture was mixed with 99.9 % EtOH until 
the final percentage of EtOH reached 70 %. After standing in -20 °C for 15 minutes, 
the plasmid was harvested by centrifuging at 12,000 g for 15 minutes at 4 °C. 
Supernatant was discarded and pellet was dried completely by vacuum and then 
resuspended in 12 |iL of sterile H2O. Plasmid concentrations were determined by 
measuring OD260 and adjusted to 1 \x%l\iL. 12 [iL of sample containing 0.5 |ig of 
plasmid and 1 X DNA loading dye was analysed by TAE agarose gel electrophoresis 
to confirm the linearization of plasmid. 
3.2.3 Preparation ofKMllH Competent Cells 
P. pastoris strain KM71H glycerol stock was streaked on a Yeast Extract 
Peptone Dextrose (YPD) plate [1 % (w/v) yeast extract (GE Healthcare), 2 % 
peptone (w/v) (Becton, Dickinson and Company), 2 % (w/v) glucose and 2 % (w/v) 
agar] and then incubated at 28 °C until colonies formed. A single colony inoculated 
in 10 mL of YPD medium was shaken at 28 °C overnight at 250 r.p.m. until OD^QO at 
2 - 6 was reached. 1.5 mL of the culture was harvested and resuspended in 1.5 mL of 
sterile H^O，followed by 0.75 mL of H2O，0.5 mL and 50 |aL of 1 M sorbitol (Sigma) 
at 4 °C respectively. 
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3.2.4 Electroporation 
Eighty microliter of KM71H competent cells mixing with 10 |iL of linearized 
plasmid were transferred to Eppendorf Electroporation Cuvette with 2 mm gap width 
(Eppendorf) and then incubated on ice for five minutes. The cuvette was pulsed by 
Eppendorf electroporator 2510 (Eppendorf) with the following parameters: 5 kV/cm, 
10 |iF, 600 CL and 5 ms. 1 mL of 1 M sorbitol was immediately added and 
the mixture was incubated at 28 °C for 90 minutes. It was then spreaded on Yeast 
Extract Peptone Dextrose Sorbitol (YPDS) plate (YPD plate with 1 M sorbitol and 
100 )ig/mL of zeocin). The YPDS plates were incubated at 28 °C for three to 
ten days until colonies formed. 
3.2.5 Colony PCR 
The procedures mentioned in section 2.3.5 (p.37) was performed except 
KM71H transformants were streaked to another YPDS plate and incubated at 2 8 � C 
for three to ten days until colonies formed. 
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3.2.6 Protein Expression Induction and Time Course Study 
A KM71H trasnformant was inoculated in 1 mL of Buffered Glycerol-
Complex Medium (BMGY) (pH 6.0) [1 % yeast extract, 2 % peptone, 1.34 % (w/v) 
yeast nitrogen base without amino acid (Sigma), 132mM dibasic potassium 
phosphate, 868mM monobasic potassium phosphate, 0.00004 % (w/v) biotin and 
1 % glycerol] and then shaken at 28 °C overnight at 250 r.p.m. The inoculum was 
sub-cultured to 100 mL of BMGY and further shaken at 28 °C at 250 r.p.m. 
overnight until mid-log phase (OD^QO = 2 - 6 ) was reached. 
Harvested yeast cells were resuspended in 10 mL of Buffered Methanol-
Complex Medium (BMMY) (pH 6.0) containing BMGY except glycerol was 
" replaced by 0.5 % (v/v) methanol (MeOH). The cultures were shaken at 28 °C for 
ten days at 250 r.p.m. for protein expression induction. 1 mL of culture was saved 
everyday and stored at -20 °C for expression level analysis. Final percentage of 
0.5 % MeOH was added everyday to compensate evaporation. Recombinant protein 
in medium was purified by affinity chromatography. 
3.2.7 Deglycosylation 
A mixture containing the recombinant protein, 1 X of G7-buffer, 1 % (v/v) 
NP-40 and 0.2 i^L of Peptide-N-glycanase F (PNGase F) (New England BioLabs) 
was digested at 37 °C for one hour. Deglycosylated protein was analysed by 
SDS-PAGE. 
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3.3 Protein Analysis 
3.3.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
Ten microliters of total lysate, supernatant and flow through and 20 \iL of 
eluent in 1 X SDS Loading dye [50 mM Tris (pH 6.8), 100 mM DTT, 2 % (w/v) 
sodium dodecyl sulfate (SDS), 0.1 % bromophenol blue and 5 % glycerol] were 
boiled at 100 °C for five minutes for protein denaturation. In the meanwhile, 10 %, 
12 % or 15 % SDS-polyacrylamide gel of 1 mm thick was prepared. 
The samples were loaded to wells of the SDS-polyacrylamide gel. At the 
same time, 2 \iL of high range protein markers (GE Healthcare) or low range prointe 
markers (GE Healthcare) in 1 X SDS Loading dye were loaded in parallel. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed at a voltage of 
180 V until dye front was just departed from the gel. The gel was stained in staining 
solution [45 % EtOH, 10 % (v/v) acetic acid and 0.24 % bromophenol blue], 
followed by destaining in detaining solution (30 % EtOH and 10 % acetic acid) until 
background colour was removed. 
In order to determine the target protein amount, various amounts of bovine 
serum albumin (BSA) were subjected to SDS-PAGE. The target protein amount was 
estimated by comparing band intensities. 
3.3.2 Western Blotting 
After SDS-PAGE, proteins in the gel without staining were transferred to 
the PVDF transfer membrane, which was equilibrated by 70 % EtOH followed by 
transfer buffer (25 mM Tris-HCl, 200 mM glycine and 10 % MeOH). Transfer was . 
performed using the Semi-dry electroblotter (OWL separation systems) at a voltage 
of 15 V for 75 minutes. 
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The membrane was immersed in PBS with 0.1 % (v/v) 
polyoxyethylenesorbitan monolaurate (PBST) with 5 % (w/v) skimmed milk powder 
to block unbounded area. Then, it was probed by immersing in 5 mL of PBS-T with 
5 % milk powder and primary antibody with gently shaking at 4 °C overnight. 
The antibody was either mouse monoclonal anti-GST antibody (Santa Cruz 
Biotechnology) or anti-His antibody (Santa Curz Biotechnology) in dilutions of 
1:1000 and 1:200 respectively. After washing five times with PBST, the membrane 
was probed by gently shaking in 5 mL of PBS-T with 5 % milk and anti-mouse 
horseradish peroxidase (HRP)-linked secondary antibody in a dilution of 1:2500 at 
room temperature for one hour. After further washing for five times, the membrane 
was immersed in 150 \iL of Enhanced Luminol Reagent and 150 \iL of Oxidizing 
Reagent of Western Lightning Chemiluminescence Reagent (PerkinElmer). Signals 
were captured by Fuji Super Rx Film (FUJI Photo products Co. Ltd.). 
3.3.3 Mass Spectrometry 
After SDS-PAGE，selected target bands were isolated and sliced into small 
pieces. Each sample was gently shaken in 1 mL of coomassie blue destaining 
solution [75 mM ammonium bicarbonate (NH4HCO3) and 40 % EtOH]. After 
destaining and washing by H2O, the sample was incubated two times in 100 |xL of 
200 mM NH4HCO3 for ten minutes, followed by 100 \iL of acetanitrate (ACN) for 
five minutes. After completely dried by vacuum, the gel was stayed in 10 |iL of 
trypsin solution [200 ng of trypsin (Promega) and 50 mM (NH4)2C03] on ice for 
30 minutes. 50 mM (NH4)2C03 was added until the gel was just covered and 
incubated at 3 0 � C overnight for trypsin digestion. Next, it was sonicated for ten 
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minutes in the presence of 20 |iL of 50 mM (NH4)2C03. 2 |iL of sample was 
transferred to the Matrix-Assisted Laser Desorption lonisation (MALDI) Sample 
Plate. Detailed procedure of the mass spectrometric analysis can be found in sections 
4.4.4 and 4.4.5 (p.59). 
3.3.4 N-terminal Sequencing 
One hundred picomoles (3 )j.g) of recombinant protein was transferred to 
a PVDF membrane. The membrane was stained by coomassie blue staining solution 
[0.5 % (w/v) coomassie brilliant blue, 40 % MeOH and 10 % acetic acid] for 
30 seconds and then destained by distilled H2O. The protein on the membrane was 
isolated and sequenced by Precise Peptide Sequencing System 492. 
3.3.5 Size Exclusion Chromatography 
The eluent was further purified by using ATKA Prime Plus (GE Healthcare) 
connecting to equilibrated HiLoad 16/60 Superdex 200 preparative grade column 
(GE Healthcare). After filtering and injection, the sample was passed through 
the column with a flow rate of 3 mL/min. 2 mL of each fraction was collected while 
real-time OD280 was recorded by "PrimeView 5.0" (GE Healthcare). The size of 
the target protein was determined by comparing the elution volumes of the target 
protein and standard proteins including Blue dextran (Void volume), Ferritin 
(440 kDa), Ovalbumin (43 kDa) and Ribonuclease A (13.7 kDa) (GE Healthcare). 
Finally, the proteins in different fractions were analysed by SDS-PAGE. 
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Identification of Interacting 
Partner(s) 
4.1 Vero E6 Cell Preparation 
4,1.1 Cell Culture 
Vero E6 cells originated from fetal rhesus monkey kidney cells are 
SARS-CoV susceptible. They were cultivated in 150 mm flasks in Dulbecco's 
Modified Eagle Medium (DMEM) (pH 7.4) with 10 % (v/v) fetal bovine serum 
(Invitrogen Life Technology) and 5 % (v/v) penicillin-streptomycin (Invitrogen Life 
Technology) at 37 °C with the supply of 5 % (v/v) carbon dioxide. To prepare 
Vero E6 total lysate, cells of 70 % 一 90 % confluence were washed by PBS and 
detached by trypsin digestion (Invitrogen Life Technology). Approximately 90 % 
Vero E6 cells were harvested by centrifugation at 1,000 g for three minutes. 
After washing with PBS, the harvested cells were stored at -80 °C. The remaining 
cells were used further for propagation. 
4丄2 Protein Extraction and Western Blotting 
To screen interacting partners, 1 g of Vero E6 cells with approximately 
5 X 109 cells were lysed by 10 mL of mammalian cell lysis buffer [50 mM Tris 
(pH 7.4), 70 mM NaCl, 1 % triton X-100 and one-fifth of protease inhibitor cocktail 
tablet (Roche)]. After shaking gently for two hours at 4 °C, the lysate was 
centrifuged at 1,000 g for five minutes at 4 °C and then the supernatant was stored at 
4 °C for pull-down assay. 1 ^L of total lysate, supernatant and pellet were analysed 
by SDS-PAGE. The membrane was probed by mouse monoclonal anti-hACE2 
antibody (R&D systems) at the dilution of 1:200. 
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4.2 Pull-down Assay 
One hundred micrograms of purified GST-Sl and 50 |ag of purified GST 
mixed with 600 i^ iL and 300 |iL of equilibrated glutathione sepharose respectively 
were gently shaken at 4 °C for one hour. To screen Vero E6 interacting partners, 
GST-S1 and GST immobilized on glutathione sepharose were washed by 1 mL and 
0.5 mL of mammalian cell lysis buffer respectively. Afterwards, the glutathione 
sepharose bound to GST-Sl was divided into two portions. 5 mL of lysis buffer with 
soluble Vero E6 lysate was added to one portion while 5 mL of lysis buffer without 
proteins was added to another portion. Another 5 mL of lysis buffer with soluble 
lysate was added to glutathione sepharose bound with GST. The samples with bound 
GST and without lysate acted as negative controls to identify non-specific binding 
proteins (Table 4.1). After gently shaking at 4 � C for two hours, they were washed 
for five times with 1 mL each of mammalian cell lysis buffer. GST-fusion proteins 
with interacting partners were eluted three times by 100 |JL of mammalian cell lysis 
buffer with 10 mM reduced glutathione. Eluents were pooled together for 
future analysis. 
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Table 4.1 - Putative proteins presented in eluents of samples and negative 
controls, z represents proteins that are only present in eluent of GST-Sl with 
Vero E6 proteins, x： represents proteins are present in the eluents of negative controls 
as well. 
G S T - S G ^ 
Protein presented in eluent + GST-S + 
Vero E6 Vero E6 
GST-S X X 
GST tag ^ 
Bacterial proteins binding to S 乂 乂 
Bacterial proteins binding to GST X X X 
Bacterial proteins binding to resin 乂 乂 乂 
Vero E6 proteins binding to S 
Vero E6 proteins binding to GST X 乂 
Vero E6 proteins binding to resin 乂 乂 
Vero E6 proteins binding to ^ 
bacterial proteins that bound to S 
Vero E6 proteins binding to ^ ^ 
bacterial proteins that bound to GST 
Vero E6 proteins binding to ^ ^ 
bacterial proteins that bound to resin 
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4.3 Two-dimensional Gel Electrophoresis 
4.3.1 Isoelectric Focusing 
Proteins in the eluent of mammalian cell lysis buffer were precipitated by 
providing nine volume of 99.9 % EtOH followed by centrifuging at 14,000 g for 
15 minutes at 4 °C. Each sample in form of pellet was resuspended in 250 |JL of 
rehydration solution [8 M urea, 0.5 % (w/v) CHAPS (GE Healthcare), 0.2 % (w/v) 
DTT, 0.5 % (v/v) Immobilized pH gradient (IPG) buffer (GE Healthcare) and 
0.002 % bromophenol blue] 
After centrifugation at 12,000 g for ten minutes, each supernatant was applied 
into a 13 cm strip holder (GE Healthcare). A 13 cm pH 3 - 10 strip (GE Healthcare) 
was placed with the gel side down. The anodic end of the strip was positioned toward 
the pointed end of the strip holder. After removing bubbles, the strip was entirely 
covered by IPG cover fluid (GE Healthcare). Isoelectric focusing (lEF), the first 
dimensional gel electrophoresis, was performed by Ettan IPGphor III isoelectric unit 
(GE Healthcare) with the following: 30 V for ten hours or more, 500 V for one hour, 
1,000 V for one hour, and then at 8,000 V (or maximal voltage) until 16,000 Vhr was 
reached. The maximum current of electrophoresis per strip was 50 f^A. The strip 
after electrophoresis was stored in -80 °C or immediately prepared for the second 
dimensional gel electrophoresis. 
4.3.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
Before SDS-PAGE, each strip was equilibrated in 10 mL of equilibration 
solution (2 % SDS，50 mM Tris (pH 8.8)，6 M Urea, 30 % glycerol and 0.002 % -
bromophenol blue) with 100 mg of DTT for 15 minutes with gently shaking, 
followed by 10 mL of equilibration solution with 250 mg of lodoacetamide (I A A). 
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Meanwhile, a 12 % SDS-polyacrylamide gel, which was 14 cm width, 16 cm height 
and 1.5 mm thick, was prepared for each strip. Gel solution was applied until 
approximately 5 mm height of space was left. 
The equilibrated strip was placed on the top of the SDS-polyacrylamide gel 
so that the strip of the gel did not touch the glass. A 5 mm wide filter paper 
containing 2 |LIL of high range molecular weight marker or full range marker 
(Invitrogen) was placed in parallel. The strip and the paper were covered by adding 
SDS-running buffer (25 mM Tris-HCl, 250 mM glycine, 0.1 % SDS with 0.5 % 
agarose and 0.002 % bromophenol blue). SDS-PAGE was performed at a voltage of 
180 V until the tracking dye was just departed from the gel. 
4.3.3 Silver Staining 
The gels were stained by silver staining kit (GE Healthcare). Each gel was 
shaken in 250 mL of fixation solution (40 % EtOH and 10 % acetic acid) for 
30 minutes followed by incubation in 250 mL of sensitizing solution [30 % EtOH, 
0.2 o/o (w/v) sodium thiosulphate, and 17 g of sodium acetate]. After washing three 
times by 250 mL each of H2O for five minutes, the gel was shaken in 250 mL of 
silver reaction solution [0.25 % (w/v) silver nitrate solution and 0.148 % (w/v) 
formaldehyde] for 20 minutes. After washing twice by 250 mL each of H2O for one 
minute, the gel was shaken in 250 mL of developing solution (6.25 g of sodium 
carbonate and 0.0074 % formaldehyde) until dark spots were developed. The 
developing reaction was stopped by immersing the gel in 250 mL of stopping 
solution (3.25 g of EDTA-Na2-2H20) for ten minutes. Finally, the gel was stored in 
H2O. Nano-pure H2O was used in all procedures. 
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4.4 Mass Spectrometry 
4.4.1 Destaining 
Selected spots stained by silver staining were isolated and destained by 20 jiL 
of solution (15 mM potassium ferricyanide and 50 mM sodium thiosulphate). When 
the color was entirely removed, the sample was washed by H2O and then incubated 
twice in 100 i^L of 200 mM (NH4)2C03 (Sigma) for ten minutes. 
4.4.2 In-gel Digestion 
The destained gel was dehydrated twice by 100 |iL of ACN. After completely 
dried by vacuum, the gel was incubated in 10 pL of solution [200 ng of trypsin and 
50 mM (NH4)2C03] on ice for 30 minutes. 50 mM (NH4)2C03 was added until 
the gel was just covered and the mixture was incubated at 30 °C overnight for trypsin 
digestion. 
The digested gel was sonicated for ten minutes in the presence of 20 |JL of 
50 mM (NH4)2C03 and the supernatant was saved. The sonication procedures were 
repeated for three times except 50 mM (NH4)2C03 was replaced by a solution 
[50 % (v/v) ACN and 2.5 % (v/v) trifluoroacetic acid (TFA)]. Then, the sonication 
procedures were further repeated by using 10 joL of ACN. Finally, all stored 
supernatants were mixed and dried by vacuum. 
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4.4.3 Desalting by Zip- Tip 
Each vacuum-dried sample was resuspended in 10 |JL of 0.1 % TFA. 
Afterwards, by pipetting up and down slowly, Ziptip (Millipore) was wet twice by 
10 i^L of 50 % ACN and then equilibrated twice by 10 [lL of 0.1 % TFA. 
Peptides were bound to the resin in the Ziptip by pipetting ten more times. 
After washing five times by 10 \xL of 0.1 % TFA, the peptides in Ziptip were eluted 
by 2 |iL ofelution solution (50 % ACN and 0.1 % TFA). 
4.4.4 Loading Sample 
Elution solution containing peptides was transferred to 192 Well Stainless 
Steel MALDI Sample Plate (Applied Biosystems) for mass spectrometric analysis. 
Finally, 0.5 \xL of matrix solution [10 mg/mL of cinnamic acid (Sigma), 50 % ACN 
and 0.1 % TFA] was added to dried pellets for crystallization. 
4.4.5 Peptide Mass Detection and Data Analysis 
Peptide masses were detected by 4700 Proteomics Discovery System 
(Applied Biosystems) including Matrix-Assisted Laser Desorption lonisation-time of 
flight-time of flight (MALDI-TOF-TOF) mass spectrometer. The peptide mass 
fingerprints (PMFs) were submitted to online databases including NCBI, Swiss-Prot 
and TrEMBL for analysis via "GPS Explorer" as well as another two searching 
algorithms, including Mascot (http://www.matrixscience.com/search_form_select. 
html) and Aldente (http://www.expasy.org/tools/aldente). The search parameters 
were listed in table 4.2. If a known protein was analysed by mass spectrometry, its 
a. a. sequence was submitted to "Peptide mass" (http://ca.expasy.org/tools/peptide-
mass.html) in order to predict PMFs. 
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Table 4.2 - Search parameter of PMFs. 
—Databases NCBI / Swiss-Prot / TrEMBL 
Species All species, mammalian, bacteria, viruses 
Peptide mass tolerance 100 ppm 
Peptide masses Monoisotopic, [M+H]+ 
Enzyme Trypsin 
Allow for One missed cleavage site 
Mass exclusion list Trypsin : 
842.508 1045.564 2225.12 2299.176 
897.531 1940.953 2239.105 2465.199 
904.468 2211.105 2283.181 
Keratin: 
1011.500 1338.500 1699.825 2288.954 
1037.527 1357.696 1707.773 2312.148 
1060.564 1357.719 1716.852 2383.900 
1066.499 1365.640 1838.915 2383.952 
1179.601 1373.655 1993.977 2510.132 
1184.591 1383.691 2083.017 2705.162 
1193.617 1434.771 2093.087 2807.250 
1234.680 1475.785 2221.100 2831.195 
1296.685 1570.677 2230.105 3312.309 
1307.678 1638.860 2230.170 3337.600 
1320.583 1657.793 2239.175 3338.700 
GST-Sl: 
927.5258 1140.5167 1310.6752 1779.8296 
963.5298 1154.5629 1480.6914 1804.8864 
1046.5629 1257.7313 1576.8733 2011.9946 
1085.5374 1258.6102 1756.9915 2534.2272 
GST: 
1011.6309 1516.8039 2045.0338 2326.1403 
1032.5870 1801.9476 2269.1386 2357.2063 
1182.6841 
GroEL: 
875.4482 1201.6535 1580.3970 1845.9188 
921.5040 1238.6600 1589.8897 2010.9510 
985.5676 1291.6562 1605.8594 2399.2776 
1000.5673 1373.7028 1640.8714 2632.3498 
1011.5217 1385.7933 1668.8084 2851.3301 
1045.5524 1454.6394 1711.7769 3239.7238 




S Protein Expression 
5.1 Plasmid Construction 
Six PCR products encoding S protein fragments were amplified by PCR and 
examined by TAE agarose gel electrophoresis in order to clone into pPICZa-A 
(Figure 5.1). The results of the cloning of other PCR products into pGEX-6P-l, 
pET-28a and pRHisMBP were similar. 
bp M 1 2 3 4 • 5 6 
10000 
3000 
2 5 � 
Figure 5.1 - Amplification of DNA encoding S glycoprotein fragments. Six PCR 
products were amplified and their sizes were same as expected. M: lOOObp marker. 




After ligation and transformation, the presence of pPICZa-A-Sl in 
transformants was examined by colony PGR using vector primers, a-F and AOXI-R 
(Figure 5.2). The results of the cloning of other constructs were similar. 
bp M l pPICZa-A-Sl j E N 
10000 pPICZa-




2 5 � 
Primer 
I H ^ H H H i l l l l i ^ i m H ^ ^ ^ H i H l i i ^ ^ l l i l ^ ^ ^ ^ l ^ ^ ^ ^ H dimer 
Figure 5.2 一 Colony PCR of pPICZa-A-Sl. 2.2 kb PGR products were specifically 
amplified by using a few of pPICZa-A-Sl transformants as template. M: 1000 bp 
marker. pPICZa-A-Sl: Transformants as template. E: pPICZa-A as template. 
N: No template. The orange, grey and black arrows indicate expected locations of 
the PCR products of pPICZa-A-Sl, pPICZa-A and primer-dimer. 
Plasmids in at least two transformants were amplified by small-scale plasmid 
amplification. Their average concentrations and OD26(/OD28o ratios were 
approximately 100 ng/|a,L and 1.8 respectively. After sequence analysis, the plasmids 

















































































































































































































































































































































































































































































































































































































5.3 Protein Expression and Optimization in E. coli 
5.3.1 Comparison of Expression Levels，Solubility and Purities of S Protein 
Fragments 
Expressions of six S fragments with GST-, His- and His-MBP-tags were 
induced by 0.2 mM of IPTG at mid-log phase and expressed in E. coli strain BL21 at 
25 °C for four hours. After purification by affinity chromatography, total lysate, 
supernatant, flow through and eluent of each fragment were examined by 
SDS-PAGE in order to determine the expression level, solubility, binding affinity 
towards resin and purity respectively. The identities of proteins were confirmed by 
western blotting analysis. 
The expression levels and solubility of four short GST-fusion proteins were 
higher than that of GST-S2 while that of GST-Sl was the lowest (Figure 5.3 A-C). 
The yields of GST-fusion proteins purified from 50 mL of E. coli were 5fig or less 
(Table 5.2). However, the solubility and purity of proteins were generally low. 
Besides non-specific binding proteins, a protein of 60 kDa in size could not be 
removed by affinity chromatography. 
The six His-fusion proteins with expected sizes could be expressed but were 
completely insoluble (Figure 5.3 D and Table 5.2). On the other hand, the expression 
levels and solubility of His-MBP-fusion proteins were similar or higher than that of 
GST-fusion proteins (Table 5.2). Their purities were however much lower than that 
of GST-fusion proteins (Figure 5.3 A and E). Since SI was predicted to interact with 
the receptor, GST-Sl was selected for the optimization of expression conditions and 
further purification. . 
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Table 5.2 - The estimated amounts of partial purified S protein fragments. 
Protein expression was induced by 0.2 mM of IPTG at mid-log phase of E. coli strain 
BL21 and shaken at 25 °C for four hours. The protein amounts were estimated by 
comparing the band intensities with BSA of known amounts. 
~ ~ a. a. residues GST-tag His-tag His-MBP-tag— 
13-672 (SI) <10 |Lig/L 0 |Lig/L <10 ^g/L 
680-1192 (S2) <10 |Lig/L 0 jug/L 0 |ag/L 
15-317 100 |Lig/L Ong/L 250 |Lig/L 
318-510 100 ng/L O^g/L 300 ^ig/L 
587-826 100 ^g/L 0 ^g/L 600 |Lig/L 
903-1187 100 iiig/L O^g/L 1500 ^ig/L 
(A) I GST-Sl II GST-S2 1 
kDa H T S F E T S F E 
220 k M f 
� I 
擎~ ^ ^ ^ GST-S2 
66 ^ ' ^ m m W P i V m F ^Non-target 
— , f _ _ — — T protein 
4 6 � , • • , • _ _ 
• mmrn 
30 ^ i f c ^ S 二 一 面 气 ” 
、 蘭 • ••觀 
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(B) I GST-( 15-317) 11 GST-(318-510) 1 
k D a H T S F E T S F E 
220 M 
98 p M i [ § ' • ‘ * — fe ‘ m _ 
: 書 * • • . " 釋 " ^ • . . � ‘ 灿 » ^ ^ y T f Non-target 
6 6 ， R F 
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(C) I GST-(587-826) II GST-(903-l 187) 1 
k D a H T S F E T S F E 
220 〜 — — 
9 8 U ^ . � y …‘ 一 一 ’ N 
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(D) I His-S 1 11 His-S2 1 
k D a H T S F E T S F E 
220 M 
卞 、 
9 8 运 二 His-Sl 
66 " ^ H B S S M S 5 ~ 
: i i i j i i 
(E) I His-MBP-S 1 11 His-MBP-S2 1 
kDa H T S F E T S F E 
'•"•PHI . -
220 im4 
^ ^ ^ ^ 和 HM-Sl 
98 ，. ^ u m i i i ^ “ 一•.一 ^ H M - s 2 
66 • i i ^ B ? ? ^Non-target 
T ^ ^ ^ ““ protein 
46 
MmmmmW^m 
Figure 5.3 - Purification of S protein fragments with GST-, His- and His-MBP-
tags. Target bands of (A) GST-Sl, GST-S2, (B) GST-(13-317), GST-(318-510)， 
(C) GST-(587-826) and GST-(903-l 187) with expected sizes were observed in total 
lysates and eluents. A protein band of 60 kDa was detected in each eluent. (D) Target 
bands of His-Sl and His-S2 could be observed in total lysates but not eluents. 
(E) Results of SI and S2 with His-MBP-tag were similar to that with GST-tag but 
a high proportion of unrelated bands were detected in eluents. H: High range marker. 
T: Total lysate. S: Supernatant. F: Flow through. E: Eluent. Red, green, orange, 
purple and blue arrows represent expected locations of SI, S2, GST-(15-317) and 




5.3.2 Alteration of the Soluble Protein Amount in Various Cell Strains， 
Expression Conditions and Lysis Buffers 
Other E. coli strains, Rosetta 2，C41 and Origami, expressing GST-Sl in 
different expression temperatures and expression levels were examined. Nonetheless, 
amounts of soluble GST-Sl in other strains were similar, while that expressed at 
37 °C were slightly lower than that at 2 5 � C , suggesting that S protein expressing in 
a higher temperature leads to a high degree of degradation (Figure 5.4). On the other 
hand, no increase in soluble protein amount was detected when the expression 
duration was altered to three hours, six hours and overnight (Figure 5.4). Thus, 
the expression duration was not an important factor to control expression levels and 
soluble protein amounts. In conclusion, lowering expression temperature might be 
a possible method to raise the amounts of soluble GST-S proteins. 
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(A) I GST-SI 1 
kDa H 1 2 3 4 5 6 7 
220 产 




46 % 一 
一 . - 、 ， 、 • • 
(B) I GST-Sl 1 
kDa H 1 2 3 4 5 6 7 
220 — 
• 




46 — . ^ ^ 
^ 
Figure 5.4 - GST-Sl expression at temperature and time. (A) SDS-PAGE and 
(B) western blotting showed that the soluble GST-Sl amounts expressed in various 
lengths of time were similar while that expressed at 37 °C were lower. The total 
lysate was presented in each western blotting analysis as internal control. 
H: High range marker. 1 - 3 : Supernatant expressed at 2 5 � C for three hours, 
six hours and overnight. 4 - 6 : supernatant expressed at 37 °C for three hours, 
six hours and overnight. 7: Total lysate at 25 °C for three hours. The red arrow 
represents GST-Sl location. 
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Solubility of GST-Sl expressed at 1 6 � C overnight was improved and 
the yield of purified GST-S 1 was increased to 25 )Lig/L (Figure 5.5). However, 
the 60 kDa protein as well as other non-target proteins was still present, revealing that 
no beneficial effect on the protein purity can be obtained by lowering expression 
temperature. 
I GST-Sl 1 
kDa H T S F E 
220 f ^ 
% 
9 8 ^ ^ a u M t a i W ^ GST-Sl 
66 I 
..• � ^ Non-target � protein 
46 
^ mr 
30 V , 
Figure 5.5 - GST-Sl expression at a lower temperature. The amount of GST-S 1 
expressed at 16 °C was similar in the total lysate but increased in eluent. 
The non-target band of 60 kDa and other unrelated bands were still presented. 
H: High range marker. T: Total lysate. S: Supernatant. F: Flow through. E: Eluent. 




In order to further improve the solubility as well as the purity, E. coli 
expressing GST-Sl was lyzed by another four kinds of buffer: 1) GST buffer with 
100 mM DTT; 2) GST buffer with 1 M Urea; 3) GST buffer with 1 % of Triton 
X-100; and 4) PBS. SDS-PAGE analysis showed that GST-Sl solubility was 
increased in three of these buffers (Figure 5.6). The amount of soluble GST-Sl lyzed 
in PBS was maximal, which was approximately five fold higher than that lyzed in 
GST-buffer. Furthermore, the 60 kDa non-target protein was reduced without 
reducing the amount of GST-Sl when E. coli was lysed in 1 M urea (Figure 5.6). 
These results indicated that PBS with urea might help in increasing the GST-Sl 
solubility and purity. 
I GST-Sl 1 
kDa H 1 2 3 4 
* 
220 4 
98 • 一 _ _ _ _ H I P 和 GST-Sl 
66 ^ ^ ^ ^ ^ ^ ^ Non-target 
^nmmp^ - ^ • • H F protein 
46 • 善 
30 
Figure 5.6 一 Solubility of GST-Sl in various lysis buffers. The amounts of purified 
GST-Sl in the four buffers were shown. H: High range marker. 1: GST buffer. 
2: GST buffer with 1 M urea. 3: GST buffer with 1 % Triton X-100. 4: PBS. 




5,3.3 Identification and Removal of non-target proteins 
Since the difference between molecular weights of GST-S 1 and the non-target 
protein was 40 kDa, separation by size exclusion chromatography (SEC) was 
performed. GST-S 1，which had been purified by affinity chromatography, was further 
purified by HiLoad 16/60 Superdex 200 column. They were nevertheless eluted 
together in the void volume (Figure 5.7). SDS-PAGE analysis showed both GST-Sl 
and GroEL were present in this peak, even their elution volumes in this peak were 
slightly varied, suggesting that they were bound together (Figure 5.8). 
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Void volume 440 kDa 43 kDa 13.7 kDa 
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Figure 5.7 - Purification of GST-Sl by SEC. Only a single peak was eluted 
at 44 mL, which was the void volume by comparing with standards. Volume of 
each fraction was 2 mL. Green arrows indicate elution volumes of standards. 
I GST-Sl 1 
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Figure 5.8 - GST-Sl after purification by SEC. GST-Sl as well as the 60 kDa 
non-target protein and little amount of other non-target proteins were eluted in 
the void volume. H: High range marker. Number: Fraction number of SEC on 
figure 5.7. The red and blue arrows represent locations of GST-Sl and the 60 kDa 
non-target protein respectively. 
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PMF showed the 60 kDa non-target band is a bacterial chaperone called 
GroEL (Figure 5.9 and Table 5.3). The role of this protein in bacterial is to help in 
folding of unfolded or misfolding proteins. It forms a 14-mers cage and binds to 
hydrophobic region of the unfolded or misfolded proteins (Landry et aL, 1994; 
Schmidt et al, 1994; Van der Vaart et al., 2004). By using ATP as substrate, 
the unfolded or misfolded protein is refolded and then released from the cage. 
Some proteins over-expressed in E. coli were bound by GroEL but released after ATP 
addition (Rohman et al., 2000; Thomas et al, 1997). However, in some cases, GroEL 
keeping protein in the native conformation was irremovable (Venkatesh et al.’ 2004). 
As it was still unknown whether the binding of S to GroEL is beneficial, we tried to 
remove the GroEL by different methods. Since only a portion of GroEL can be 
removed in the presence of 1 M urea, completely removal of GroEL was tested by 






too-i - • 
M 
70 
！ " 运“ I 
40 ^ § I <n 
s i J i i 5 
, M | J LAI ULJLIIII^^AH IIIR ^ m 
& ‘ t»'U W1J.4 “ 214S4 KfjM 
II MT IM >1 
Figure 5.9 - PMF of the 60 kDa protein. The red arrows indicate peaks matching 
GroEL. 
Table 5.3 - Peptides of the 60kDa protein matching to GroEL. Peptide masses 
were submitted to Mascot Search (http://www.matrixscience.com/search_fonn_select. 
html) for identification. 
start - End Observed Hr(expt) Hr(calc) Delta Hiss Sequence 
396 - 404 1011.5386 1010.5313 1010.5145 0.0168 0 R.VKDXLHATR.X 
66 - 75 1154.5901 1153.5828 1153.5259 0.0569 0 K.FBIH3AQUVK.E 
405 - 421 1567.9050 1566.8977 1566.8728 0.0249 0 R.»AVEESVVAa30VALIR.V 
37 - 51 1589.8849 1588.8776 1588.8824 -0.0048 1 R.IWUDKSrQAPTITK.D 
43 - 58 1605.8633 1604.8560 1604.8522 0.0039 1 K.srOXPTITRDSVSVAR.E 
328 - 345 1845.9413 1844.9340 1844.9115 0.0225 0 K.DTTTIIDOVOEKAJaQOR.V 
172 - 197 2851.3804 2850.3731 2850.3228 0.0503 0 K.E(3VITVEDOT9LQDBIJaVVE(MQrDR.3 
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RESULTS 
GroEL was removed in the presence of ATP at 37 °C but GST-Sl was 
degraded and a number of non-target proteins were detected (Figure 5.10 A). 
Removal of GroEL at a lower temperature was examined; however, both GST-Sl and 
GroEL were retained at 4 °C (Figure 5.10 B). At 25 °C, most of the GST-Sl and 
GroEL were lost. In conclusion, addition of ATP may not be a good method for 
the removal of GroEL. 
(A) (B) 
kDa H -ve 37°C kDa H 4°C 25°C 
• • - . i GST-Sl 
220 H J T - S l : M ^ 
98 66 勺 
^^ A ^ " - i Non-target 
66 , 则 - - ’ • 勺 4 6 I I protein 
. * - Non-target 
, • J — . protein 
30 • • 
30 • ； 21 
21 14 • • 
Figure 5.10 - Remove of GroEL by ATP in various temperatures. (A) GroEL was 
removed in presence of ATP but GST-Sl was lost as well. More non-target proteins 
were detected at 37 °C. (B) Both of GST-Sl and GroEL was retained at 4 °C but most 
of them were lost at 25 °C. H: High range marker, -ve: Without ATP at 37 °C. 
Number: With ATP at temperatures. The red and blue arrows represent locations of 
GST-Sl and the 60 kDa non-target protein respectively. 
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RESULTS 
On the other hand, GroEL was removed after washing by PBS with urea 
(Figure 5.11). Increase in the urea concentration of PBS caused loss of both GST-Sl 
and GroEL in eluents but the degree of the loss of GST-Sl was lower than that of 
GroEL. In PBS with 2M of urea, GST-Sl was still retained while GroEL was 
removed. However, other non-target proteins were still present in eluents. Thus, 
the sample was subjected to SEC. Elution profile and SDS-PAGE analysis showed 
that GST-Sl in the absence of GroEL was still eluted in the void volume, suggesting 
that GST-Sl formed aggregates or bound to other bacterial proteins (Figure 5.12 
and 5.13). 
kDa H 1 2 3 4 5 6 7 8 9 
220 • . 
GST-Sl 
98 •丨4_丨丨|—• — _ • •_ 
66 . ‘ 
Non-target 
4 6 ‘ protein 
30 l i l ^ 
Figure 5.11 - Loss of GroEL in various urea concentrations. Both GST-Sl and 
GroEL in eluents were lost when the urea concentration of PBS was raised. In PBS 
with 2 M of urea, GST-Sl without loss had the highest purity. H: High range marker. 
1 - 9: 0 M, 0.5 M, 1 M, 1.25 M, 1.5 M, 1.75 M, 2 M, 2.25 M and 2.5 M of urea. 
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Figure 5.12 - Analysis of GST-Sl after the removal of GroEL by SEC. 
Only a single peak was eluted at 49 mL, which was the void volume by comparing 
with standards. Volume of each fraction was 2 mL. Green arrows indicate elution 
volumes of standards. 
I GST-Sl 1 
kDa H 5 6 7 8 9 
220 
9 8 m m m g s t - s i 
6 6 i M f H Non-target 
protein 
46 
30 m m m 
21 
Figure 5.13 - GST-Sl without GroEL after purification by SEC. Both GST-Sl 
and non-target proteins were eluted in the void volume. H: High range marker. 
Number: Fraction number of SEC on figure 5.12. The red and blue arrows represent 
locations of GST-Sl and the 60 kDa non-target protein respectively. 
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RESULTS 
5.3.4 Unfolding and Refolding 
Bacterial inclusion bodies containing His-(15-317), His-(318-510), His-
(587-826) and His-(903-l 187) were solubilized in 6 M guHCl. These recombinant 
proteins were immobilized on His-binding resin, followed by washing and eluting by 
the buffer with 50 mM and 500inM of imidazole respectively. The purities of 
His-(567-826) and His-(903-l 187) were approximately 90 % while His-(15-317) and 
His-(318-510) with small amounts of non-target proteins were present in eluents 
(Figure 5.14). Mass spectrometry analysis showed that all obvious non-target bands 
were degradative products except that the 45 kDa protein in eluent of His-(318-510) 
is an elongation factor. 
kDa L 1 2 3 4 




21 • 4 
14 / m m 
Figure 5.14 - Partially purified S proteins. L: Low range marker. 1 - 4: Eluents of 
His-( 15-317), His-(318-510)，His-(587-826) and His-(903-1187). 
79 
RESULTS 
The partially purified proteins with final concentrations of 50 ng/|j.L were 
refolded in various refolding conditions by rapid dilution (Table 3.1). 
After centrifugation, supernatant was analyzed by SDS-PAGE to determine 
the recovery yields (Figure 5.15). Refolding buffer 2, one of the conditions with 
the highest yield, was selected for secondary and tertiary screening of refolding 
conditions of His-(318-510) (Table 3.1). We found that PEG and divalent cation did 
not have a significant effect on the improvement of protein solubility (Figure 5.16). 
(A) I His-(15-317) 1 
kDa L 1 2 3 4 5 6 7 8 9 
44 
—一 ^ ^ ^ ^ Jf^ ‘ mm. _•"”丨•丨11 *** 
30 
21 
14 . ‘ 
(B) I His-(318-510) 1 
kDa L 1 2 3 4 5 6 7 8 9 
44 
30 • • 
.“丨嶋 “_ _ 一 丨"I ^^mmmmrn 
21 
. ‘ 
14 • • 
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RESULTS 
(C) I His-(587-826) 1 
kDa L 1 2 3 4 5 6 7 8 9 
44 - m t m 
30 _ 關丨丨 I” I — --
21 
1 4 舊 
I-•！Mil"'-
(D) I His-(903-l 187) 1 
kDa L 1 2 3 4 5 6 7 8 9 
44 mm 




Figure 5.15 - Primary screening of refolding conditions. Unfolded (A) His-
(15-317), (B) His-(318-510), (C) His-587-826 and (D) His-(903-1187) were refolded 
in nine refolding buffers by rapid dilution. All recombinant proteins could be 
refolded in a soluble form with high recovery in a few of refolding conditions. 
L: Low range marker. 1 - 9 : Refolding buffers 1 - 9 (More details can be found in 
table 3.1, p.45). 
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RESULTS 
(A) I PEG (uM) 1 





(B) I Divalent Cation (mM) 1 






Figure 5.16 - Secondary and tertiary screening of refolding conditions of His-
(318-510). Refolding conditions of His-(15-317) were (A) secondary and (B) tertiary 
screened by rapid dilution. The amounts of soluble recombinant proteins refolded in 
various conditions were similar and that recovery rates closed to 100 %. 
L: Low range marker. 11 - 16: Refolding buffers 1 - 6 of secondary screening. 
21 - 2 7 : Refolding buffers 1 - 6 of tertiary screening. C: Total protein. 
82 
RESULTS 
To further confirm whether the protein was refolded successfully, refolded 
His-(318-510) was rapidly diluted in PBS. Small proportion of His-(318-510) 
refolded in various refolding conditions became insoluble (Figure 5.17 A). 
Nevertheless, a contradictory result was determined when refolding buffer was 
slowly removed by dialysis (Figure 5.17 B), suggesting that the proteins were soluble 
only in presence of refolding buffer, such as L-arginine. 
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RESULTS 
(A) I His-(318-510) 1 
k D a L 1 2 3 4 5 6 7 8 9 
44 , • 
！ -
30 • 身 
21 P . 
14 
(B) I His-(318-510) 1 
kDa L 11 12 13 14 15 16 17 
44 
30 
mmmrnrnmrn ‘ 丨丨•丨_麵 
21 • 
14 nigMtfi 
Figure 5.17 - Solubility of refolded His-(318-510) in PBS. (A) Little soluble His-
(318-510) refolded in various conditions became insoluble only after rapidly diluting 
in PBS. (B) The soluble His-(318-510) amount was depleted after dialysis by PBS. 
L: Low range marker. 1 — 9: Insoluble fraction of refolded protein after rapid dilution 
by PBS. 11: Total protein. 12: Refolded total protein. 13: Refolded soluble protein. 
14: Dialyzed total protein. 15: Dialyzed soluble protein. 16: Flow through. 17: Eluent. 
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RESULTS 
5.4 Protein Expression and Optimization in P. pastoris 
5.4.1 Expression Levels, Solubility and Purities of Various S Protein Fragments 
Six recombinant proteins were expressed in P. pastoris strain KM71H and 
the time courses of protein expression were studied. The secreted and intracellular 
recombinant proteins after 0，24, 48, 72，96, 120，144 and 240 hours of induction 
were purified and concentrated by His-binding resin. In the expression of 
aA-(318-510), major bands of 35 kDa in size and upper smears were detected by 
SDS-PAGE (Figure 5.18 A). The yield, which was 46mg/L, reached a maximum 
after 144 hours of induction. However, detection of other recombinant proteins by 
SDS-PAGE failed except aA-(15-317) (Figure 5.18 B). The yield reached 
a maximum after 144 hours of induction as well but the yield was only 5 mg/L. 
Western blotting analysis using anti-cmyc antibody was performed to 
determine whether the four recombinant proteins were expressed. aA-S2, 
aA-(587-826) and aA-(903-1187) were present in yeast total lysate but the amount 
of aA-(587-826) was very low (Figure 5.19), revealing that these proteins were 
expressed but not secretory. No signal was detected in yeast lysate of aA-( 13-672), 
indicating that expression failed for this fragment (Figure 5.19). 
85 
RESULTS 
(A) I aA-(318-510) 1 
kDa L 0 24 48 72 96 120 144 240 
- i i u m 
30 
21 ^ m 
1 
14 _ , 
6.5 n u t 
(B) I aA-(15-317) 1 
kDa H 0 24 48 72 96 120 144 240 
i r 
I 






Figure 5.18 一 Time course study of secretory S protein fragments. 
(A) The 35 kDa bands and upper smears were detected after 24 hours of induction of 
aA-(318-510) expression. (B) Smears of aA-(15-317) were detected. 
86 
RESULTS 
(A) I aA-Sl II aA-S2 1 






(B) h - aA-(587-826)—11—aA-(903-1187)—I 
kDa H 0 48 144 0 48 144 
66 — .. ’ M : : � 
46 一 .. HHUPP 
30 — . ' 
. . . » • 
. . . ) 
� . . . . . . -
,•,._•‘ •• -. . • - ^ 二 
Figure 5.19 - Presence of intracellular S protein fragments in P. pastoris, 
(A) Signals of aA-S2 but not aA-Sl were found in yeast lysate after induction of 
144 hours. (B) Both aA-(587-826) and aA-(903-1187) were present in the lysate but 
the aA-(587-826) amount was much lower. H: High range marker. Numbers: yeast 
lysate after hours of induction. 
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RESULTS 
aA-S2 and aA-(903-1187) in the yeast lysate were purified by affinity 
chromatography and then analyzed by western blotting using anti-cmyc antibody. 
aA-S2 was only presented in total lysate but not supernatant, showing that it was 
insoluble (Figure 5.20). On the other hand, aA-(903-1187) was detected in 
supernatant as well as eluent (Figure 5.20). Thus the expression of this fragment is 
successful and it is soluble but not secretory. 
I aA-S2 1 | - a A - ( 9 0 3 - 1 1 8 7 ) H 
kDa H T S E T S E 
220 — H H ^ j M j j l 
66 一 l ^ ^ l g l l l l ^ 
46 一 I F 
30 — 
Figure 5.20 - aA-S2 and aA-(903-1187) solubility. Signal of aA-S2 was detected 
in yeast lysate only while that of aA-(903-1187) was found in total lysate, 




5.4.2 Characterization of De-N-glycosylated Recombinant Proteins 
All sizes of major bands and smears were higher than the expected size. 
One of the possible reasons is glycosylations of the recombinant proteins 
since proteins expressed in yeast are commonly highly-glycosylated. If it is true, 
sizes of the recombinant proteins after deglycosylation should decrease to 
the expected size. SDS-PAGE analysis showed that aA-(318-510) de-N-glycosylated 
by PNGase F was 29 kDa in size and a few proteins larger than 29kDa were 
presented (Figure 5.21 A). Their sizes were still larger than 24 kDa, the calculated 
size of aA-(318-510). The increased size might be due to 0-glycosylations or 
incomplete de-N-glycosylation. Results of de-N-glycosylated aA-(15-317) and 
(xA-(903-l 187) were similar to that of aA-(318-510) (Figure 5.21 B and C). 
The possibility of the presence of a signal peptide in aA-(318-510) 
N-terminal was ruled out since N-terminal sequencing results showed that the signal 
peptide was cleaved by Kex2 but not Stel3, leading to the presence of four extra a. a. 
residues (Figure 5.22). Failure of translation termination was impossible as well 
because peptide mass fingerprint had a peak of 2126.9001 Da, which matched 
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(B) aA-(15-317) aA-(903-l 187) (C) aA-(903-l 187) 
kDa H ME ME E E kDa E E 
(PNGase) (PNGase) (PNGase) 
220 ^ ^ 98 
98 mmm ^^^^HK 
66 M g 账 6 6 — 
46 , 飄 t P ^ ^ ^ H H 
4 6 — 
30 
Figure 5.21 一 De-N-glycosylation of aA-(318-510), aA-(15-317) and aA-(903-
1187) by PNGase F. (A) Both major band and smear of aA-(318-510) were 
decreased in sizes. The major band intensity was increased while the smear intensity 
was decrease. (B, C) The sizes of smears of aA-(15-317) and aA-(903-1187) were 
decreased while their intensities were unchanged. L: Low range marker. 
H: High range marker. ME: Eluent of medium. E: Eluent of yeast lysate. 
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Figure 5.22 一 N-terminal sequencing of aA-(318-510). The N-terminal sequence of 
aA-(318-510) was EAEAEF, which was matched to the N-terminal sequence of 
the recombinant protein cleaved by Kex2 but not Stel3. Blue arrows indicate the a. a. 
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Figure 5.23 一 PMF of aA-(318-510). The peak of 2126.9001 Da matched 
C-terminal of aA-(318-510), LISEEDLNSAVDHHHHHH, with a calculated mass 
of 2126.9750 Da. The red arrow indicates the matched peak. 
The GST-(318-510) expressed in E. coli formed aggregates while the native 
conformation of RED was monomer. The native size of aA-(318-510) was 
determined by SEC. A board peak was eluted between 58 mL and 88 mL while 
the highest reading was at 78 mL (Figure 5.24). The eluents were analyzed by 
SDS-PAGE and results showed that fraction 25 contained only a band of 
aA-(318-510) but not a smear (Figure 5.25). By comparing with standards of SEC, 
native size of the protein eluted in fraction 25 was 34 kDa, which matched 
the molecular weight of aA-(318-510) determined by SDS-PAGE. In conclusion, 
aA-(318-510) was expressed in a monomeric form. The difference in the sizes of 
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Figure 5.24 - Determination of aA-(318-510) native size by SEC. A board peak 
was eluted between 52 mL and 88 mL and the peak height was at 78 mL，which was 
60 kDa by comparing with standards. Volume of each fraction was 2 mL. 
Green arrows indicate elution volumes of standards. 
kDa H 13 15 17 19 21 23 25 27 29 
220 P k 






Figure 5.25 - SDS-PAGE of aA-(318-510) purified by SEC. H: High range marker. 
Number: Fraction number of SEC on figure 5.24. 
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RESULTS 
De-N-glycoslyated aA-(318-510) was examined in order to further confirm 
its native size. The protein was nonetheless eluted in void volume, indicating that 
de-N-glycosylated aA-(318-510) was aggregated (Figure 5.26). 
— Void 
. volume 440 kDa 43 kDa 13.7 kDa 
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Figure 5.26 一 Determination of de-N-glycoslyated aA-(318-510) native size by 
SEC. aA-(318-510) was eluted at 45 mL, which was the void volume by comparing 
with standards. Volume of each fraction was 2 mL. Green arrows indicate elution 





6.1 Practicability of Pull-down Assay 
6A,1 ACE2 Extraction 
ACE2, a function receptor of SARS-CoV, binds to a. a. residue 318 - 510 of 
the S protein (Li et al., 2003; Wong et al.’ 2004). Since this protein is a TM protein 
located on Vero E6 cell surface, the presence of hydrophobic regions may deplete 
ACE2 so that it cannot be extracted. Confirmation of the presence of ACE2 after 
extraction by mammalian cell lysis buffer was therefore performed. Result of 
western blotting analysis using anti-ACE2 antibody revealed that ACE2 was present 
in soluble fractions of mammalian cell lysis buffer (Figure 6.1). On the other hand, 
less ACE2 present in the total lysate might be because of experimental error during 
transfer of Vero E6 proteins. 





30 — M ^ N N M I M 
Figure 6.1 - The detection of ACE2 in the protein extracts. ACE2 of 
approximately 120 kDa was detected in the soluble fraction of mammalian cell lysis 
buffer but not insoluble fraction. H: High range marker. T: Total lysate. S: Soluble 
fraction. P: Insoluble fraction. 
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RESULTS 
6.1.2 Pull-down of A CE2 by the P, pastoris-expressed recombinant RBD 
To confirm whether the expressed S protein was functional, pull-down assay 
using aA-(318-510) and Vero E6 cell lysate was performed. Presence of ACE2 in 
the eluate was then detected by western blotting using anti-ACE2 antibody. 
The western blotting result showed that the band representing ACE2 could be 
detected in the eluate of aA-(318-510) but not the negative control, in which 
aA-(318-510) was absent (Figure 6.2). The specific interaction between ACE2 and 
aA-(318-510) implied aA-(318-510) was functional and ACE2 as well as other 
interacting partners could be captured by pull-down assay. 
Figure 6.2 - Identification of ACE2 by pull-down assay using aA-(318-510). 
H: High range marker. 1: Presence of aA-(318-510). 2: Absence of aA-(318-510) as 
negative control. Orange arrow indicates the expected location of ACE2. 
kDa H 1 2 
220 — 







6.2 Pull-down Assay and Two-dimensional Gel 
Electrophoresis 
By comparing spots on Two-dimensional (2D) gels, approximately twenty to 
thirty spots were detectable only in the 2D gel using GST-Sl and Vero E6 cell lysate 
(Figure 6.3 and 6.4). A few of these spots were still detectable when pull-down assay 
using GST-Sl with GroEL and Vero E6 cell lysate was repeated. Interestingly, 
when we examined the results from GST-Sl purified by 2M of urea and Vero E6 cell 
lysate, locations of putative interacting partners were significantly changed. It might 
be due to the depletion of GroEL which changed the GST-Sl structure, or altered 
the amounts and conformations of other bacterial proteins. Thus, Vero E6 proteins 
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RESULTS 
(F) H pH 10< > pH 3 
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Figure 6.3 一 Protein 2D map of GST-Sl with GroEL interacting with Vero E6 
cell lysate. (A) GST-Sl with Vero E6 cell lysate, (B) GST-Sl without lysate and 
(C) GST with lyate were used for one of the trials of pull-down assay. 
(D-F) A few spots could be found in another trial of pull-down assay. Red circles 
indicate GST-Sl and GST while green circles represent spots that are detectable in 
the gel using GST-Sl and Vero E6 lysate. F: Full range marker. 
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RESULTS 
(A) H pH 10^ > pH 3 
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(B) H pHlO < > pH3 
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RESULTS 
(C) H pH 10 < > pH 3 
220 M ^ P ^ ^ ^ ^ ^ ^ ^ P P M i P — 
66 
Figure 6.4 - 2D map of proteins generated by GST-Sl purified by 2 M of urea 
and Vero E6 cell lysate. (A) GST-Sl withVero E6 cell lysate, (B) GST-Sl without 
lysate and (C) GST with lyate was used for pull-down assay. Red circles indicate 
GST-Sl and GST while green circles represent spots that are detectable in the gel 
using GST-Sl and Vero E6 lysate. H: High range marker. 
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RESULTS 
6.3 Identification of Putative Interacting Partners by 
MALDI-TOF-TOF 
The spots of putative interacting partners using Vero E6 cell lysate were 
isolated and digested by trypsin. After desalting by Ziptip, peptide masses were 
measured by MADTI-TOF-TOF. The PMFs were submitted to databases ofNCBI, 
SWISS-Prot and TrEMBL for identification. Searching results showed that two of 
these spots were Peroxiredoxin 1 (Prxl) and Heat Shock 70 kDa Protein 5 (HSPA5) 
(Table 6.1). Their apparent masses on the 2D gels were same as their experimental 
masses, which were 26 kDa and 78 kDa respectively. On the other hand, 
several spots were identified as bacterial proteins including GroEL and Heat shock 
protein 40 (DnaJ). Also, some spots were identified as other mammalian and 
bacterial proteins spots but their M. W. and pi were not matched with the observed 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.1 S Protein Expression in E. coli 
7.1.1 Improving Recombinant Protein Expression Level and Solubility 
Being an expression host, E. coli offers a means for the rapid and economical 
protein production with a high expression level, for instance, the soluble GST yield 
was more than 20 mg/L. Raising the bait (GST-Sl) amount in pull-down assay is 
beneficial to prey interacting partners with low binding affinity since the interactions 
between the bait and the interacting partners are enhanced (Wong et al., 2004). 
Besides pull-down assay, it can also be used for other studies that require huge 
protein amount, e.g. structure determination. Nonetheless, the yields of purified 
S protein fragments, especially SI and S2, were extremely low (Figure 5.3). 
Several parameters including fusion tags，host strains, temperature, expression 
duration and lysis buffer contents potentially affecting solubility were hence 
optimized in this project. 
GST- and His-MBP-tags were examined as they not only stabilize 
the recombinant protein but also increase the protein solubility (Sachdev et al” 1999; 
Terpe, 2002). These tags can bind to glutathione and amylose respectively by their 
specific conformations and hence be immobilized and purified (Di Guan et al.，1988; 
Smith et al., 1988). His-tag was tried because this short tag with six histidine 
residues minimizes the chance of altering recombinant protein structure and function 
(Hakansson et al., 2000; Terpe, 2002; Wu et al, 1999). Another reason is His-fusion 
protein can be purified under denaturing conditions, that do not influence interaction 
between His-tag imidazole ring and transition metal ions on matrix (Hochuli et al, 
1987). Additionally, combination of His- and MBP-tag for purification and 
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stabilization respectively is widely used for the expression of many recombinant 
proteins (Hamilton et al., 2002; Podmore et al.’ 2002). 
Level and solubility of protein expressed in various bacterial strains with their 
own characteristics and modifications can be altered (http://www.novagen.com/ 
SharedImages/Novagen/05_PROEXP.pdf; http://www.embl.de/ExtemalInfo/protein 
_unit/draft_frames/flowchart/exp_e_coli/Expression_Ecoli.html). First of all, BL21 
lacking Ion and ompT proteases is the most widely used expression host. 
For a protein encoded by bacterial rare codons, co-expression with tRNAs for AGG, 
AGA, CGG, AUA, CUA CCC and GGA in Rosetta 2 may reduce premature 
termination and thus increase the expression level. On the other hand, C41, a BL21 
strain with unknown mutations, was effective to express certain toxic and 
membranous proteins (Chow et al., 2005; Dumon-Seignovert et al.，2004; Miroux 
et al., 1996). Thus, it may help to express apoptosis-inducing S protein with 
a number of hydrophobic regions. Lastly, Origami with thioredoxin reductase and 
glutathione reductase mutants provides a more oxidizing cytoplasmic environment, 
which greatly facilitates disulfide bond formation and hence proper folding of 
S recombinant proteins. 
Expression temperature and time are also important factors influencing 
expression level and solubility. Higher temperature and longer expression time may 
increase expression level as well as the chances of degradation and aggregation due 
to misfolding, and vice versa (Liao，1991; Strandberg et al, 1991). Their effects on 
S protein expression are unknown and therefore examined in this project. 
Using an appropriate buffer can maintain the recombinant protein in 
the proper conformation and eliminate non-target contaminants. The buffer with high 
DTT concentration (100 mM) breaks disulphide bonds, preventing protein 
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misfolding due to abnormal disulphide bonding formation. Low concentrations of 
denaturing agents and detergents, such as 1 M of urea and 1 % (v/v) of triton X-100 
respectively, help to extract target protein and remove non-specific binding proteins. 
At last, PBS closing to physiological conditions of human was examined because 
it is widely used in similar experiments. 
Experimental results revealed solubility was increased when S protein fused 
with GST-tag, expressed at a lower temperature and lyzed in buffer with triton X-100, 
while the purity was improved after lysis in buffer with urea followed by affinity 
chromatography (Figure 5.3, 5.5 and 5.6). An unpredictable result was the protein 
lyzed in PBS had the highest solubility (Figure 5.6). A possible explanation is PBS 
with a lower salt concentration (137 mM) causes reduction of interactions between 
charged groups of protein molecules. 
After optimization, only 100 |j,g/L of soluble GST-Sl was isolated 
(Figure 5.6). Fragment sizes, fragment locations and expression conditions are varied 
in other research groups but expression levels and solubility were similar. Most of 
the fragments were expressed in insoluble form (Chen et al, 2005; Wei et al., 2005; 
Yu et al, 2003; Zhou et al, 2004; Zuo et al, 2005). Till now, a. a. residue 260 - 600， 
397 - 796, RBD and HR, but not SI and S2, were expressed in native conformations 
(Chen et al, 2005; Hakansson-McReynolds et al, 2006; Wei et al, 2005; Xu et al., 
2004; Xu et al, 2004). By refolding of inclusion bodies, soluble full-length, S2, HR 
and a. a. residue 450 一 650 were produced but native folding was not yet confirmed 
(Ho et al., 2004; Hsu et al.’ 2004; Zhao et al., 2005; Zuo et al., 2005). 
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7.1.2 S Recombinant Protein Bound by GroEL 
All expressed GST-S protein fragments in various conditions were bound by 
GroEL, which was irremovable by affinity chromatography (Figure 5.3 and 5.5). 
Similar problems were also encountered by another research group (Yu et al, 2003). 
In fact, GroEL is an endogenous bacterial chaperone preventing irreversible protein 
aggregation as well as assisting protein folding into the native conformation (Figure 
7.1) (Sakikawa et al., 1999; Taguchi et aL, 2005, Viitanen et al, 1992). It exists in 
the form of a double ring of seven subunits each with a central cavity (Braig et al, 
1994) and then links with a cofactor GroES to construct a GroEL/ES complex (Saibil 
et aL, 2002; Sigler et al., 1998). Hydrophobic residues of entrance of the central 
cavity interact with the hydrophobic residues of non-native substrate exposed on 
the surface, followed by ATP hydrolysis promoting folding, and finally releasing 
the substrate (Horwich et al., 1993; Taguchi et al., 2005; Van Dyk et al.’ 1989). 
Assistance of protein folding by GroEL is a common phenomenon because 
approximately 10 % of newly synthesized polypeptides in E. coli were the substrates 
(Ewalt et al., 1997). A characteristic of these substrates is preferentially presences of 
ap-fold，which is composed of an a-helix and buried p-sheet (Houry et al” 1999). 
The secondary structure prediction results revealed that all S protein fragments 
contain a-helix and p-sheet except RED (a. a. 318 — 510), which is confirmed by 
crystal structure analysis of RBD (Li et al.’ 2005). Hence, the interaction between 
RED and GroEL is possible to be induced by exposure of other hydrophobic motif or 
patch (Chaudhuri et al.’ 2005; Stan et al” 2006). 
Generally, the substrates were simply released in the presence of ATP but 
release of S protein by ATP failed in our project (Figure 5.10) (Grantcharova et aL, 
2001; Thirumalai et aL, 2001). Besides misfolding of S proteins, the failure suggests 
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that S proteins binding to GroEL is folded properly and thus functional (Venkatesh 
et al., 2004). Thus, pull-down assays using both GST-Sl with GroEL and GST-Sl 
purified by 2 M of urea were performed. 
Figure 7.1 一 Schematic diagram of folding mechanism by GroEL/ES complex 
(Adapted and modified from Feltham et al., 2000). 
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7.2 S Protein Expression in P. pastoris 
7.2,1 Advantages of Using P. pastoris 
P, pastoris is another high-yield, rapid and economical system for a wide 
variety of recombinant protein production. As a eukaryote, P. pastoris can also 
post-translational modified the expressed protein such as folding, disulfide bond 
formation, glycosylation and proteolytic processing. The protein structure and 
modifications are similar to that expressed in mammalian cells, for example, the core 
structure of the protein N-linked glycan formed in P. pastoris is same as that of 
mammalian cells (Tarentino et al” 1985). Therefore, the proteins expressed in 
P. pastoris should have a higher chance to be in native conformation and functional 
when compared with proteins expressed in the bacterial system. 
Secretion of recombinant protein is another great advantage of P. pastoris. 
Except low levels of endogenous proteins, the heterologous proteins with a signal 
peptide are only secreted to the medium and comprise the vast majority of the total 
protein. This would minimize purification steps and improve recovery yield. 
Moreover, low levels of endogenous proteins including proteases reduce the chance 
of protein degradation as well. 
Various yeast hosts are suitable for foreign protein expression but P. pastoris 
possesses its own benefits. Firstly, alcohol oxidase I {AOXI) gene is methanol-
inducible and tightly regulated. Before induction, energy is therefore saved for cell 
growth rather than lost for leakage of protein expression. Moreover, P. pastoris can 
be cultivated in a high density (100 g/L) and MeOH is utilized for the expression 
induction, so that space and cost required are relatively low. 
Hyperglycosylation is a common problem in various yeast hosts. P. pastoris 
is more beneficial than other hosts such as S. cerevisiae, since the longest N-linked 
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glycans in P. pastoris is approximately 8-14 mannose residues while that in 
S. cerevisiae is between 50 and 100 mannose residues (Gregg et al., 1993; Daly et al., 
2005). The glycoprotein structure and function expressed in P. pastoris is more 
similar and compatible to that expressed in mammalian systems. 
7,2.2 Variation of S Fragment Expression Levels 
Only aA-(318-510) level reached 46mg/L while the levels of other 
recombinant proteins expressed in the same conditions were much lower. Typically, 
only one-tenth of the amount of aA-(318-510) or less could be obtained (Figure 5.18 
and 5.19). A possible reason leading to the difference of expression levels of four 
S protein fragments in P. pastoris, but not in E. coli’ is the codon bias. Expression 
level of a protein encoded by rare codons can be increased by five to ten folds after 
codon optimization (Hu et al.’ 2006; Xiong et al., 2005; Xiong et al.’ 2006). 
Nucleotide sequence encoding S protein was submitted to two databases for 
rare codon analysis. Even two databases showed little diverse codon frequencies, 
both results revealed the expression levels are negatively related to the number of 
rare codons (Table 7.1). aA-(318-510) contains the lowest rare codon number, 
followed by aA-(903-l 187) and aA-(15-317). aA-(587-826) is the only exceptional 
case, in which the number of rare codons was similar to that of aA-(15-317) but 
the expression level was much lower (Figure 5.19). 
When only the lowest frequencies (2.0 or 2.2 / 1,000) in the database "Rare 
codons' Search" are considered, aA-(587-826) contains two of these codons while 
other fragments contain one or less. The numbers of these rare codons are negatively 
related to their expression levels as well. Collectively, the analysis suggested the 
expression levels of S protein fragments could be improved after codon optimization. 
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Table 7.1 - Rare codons of S protein expressed in P. pastoris. The nucleotide 
sequencing of S protein was analyzed by "Rare codons' Search" (http://molbiol.ru/ 
eng/scripts/01_ll.html) and "Graphical Codon Usage Analyzer" (http://gcua. 
schoedl.de/), that are represented by database 1 and 2 respectively. The total 
frequency is 1,000. Bold numbers in database 1 indicate the frequencies are 2 or 2.2. 
no. of a. a. ^ . a. a. residues Frequency Frequency a. a. residues of 
residues � encoded (Database 1) (Database 2) S protein 
18 “ egg Arg 2 5 | 
1 9 ugc O ^ 4 2 / 
39 ggg ^ / - 10 
68 ggg G ^ / 10 
113 u ^ ^ / 8 
126 “ cga Arg 4.4 10 
159 “ ugc Cys — 4.2 / — 
169 ucg Ser 一 / 8 15-317 
183 — cga Arg — 4.4 “ 10 
192 ggg Gly / 10 
194 ^ ^ / 8 
264 cuc / 8 
286 cuc — Leu / 8 
288 — ugc Cys 4.2 “ / 
292 一 age Ser / 9 Si 
355 cuc L ^ / 8 
366 ugc ^ / 
378 ugc Cys — 4.2 “ / oio 
398 ggg Xfe 3.8 5 —— 318-510 
467 ugc ^ ^ / 
507 “ ccg Pro — 4.2 10 一 
532 — cuc Leu / 8 
563 cga Arg — / 10 
563 cga ^ 4 4 / 
576 ugc Cys — 4.2 10 
603 “ ugc ^ / 
615 cuc / 8 
620 cgc — Arg 2.2 6 
648 — ugc Cys ~ 4.2 / 
670 — age Ser / 9 
703 age Ser — / 9 
725 — ugc Cys 4.2 _ / 
736 cuc Leu 一 / 8 ~ 587-826 
740 一 age Ser — / _ 9 
742 ugc Cys 4.2 / 
749 — cuc Leu / ~ 8 
758 cgc 6 
804 — cuc Leu ~ / 8 
810 一 cuc Leu — / 8 
822 ugc Cys — 4.2 / 
831 cuc L ^ / 8 
834 — gcg Ala — 3.8 5 
847 — cuc Leu ~ / 8 
898 cuc — Leu 一 / 8 ^^ 
902 — caa Gin / 5 
912 “ gcg — Ala 3.8 / “ 
949 age Ser ~ / ~ 9 
964 ucg Ser ~ / ~ 8 
965 cga — Arg 4.4 10 
971 gcg Ala 3.8 5 903. 
_ 9 8 5 age S ^ / 9 二 
1039 ccg Pro ^ 10 
1060 “ gcg Ala 3.8 5 
1167 “ cgc Arg — 2.2 6 
1.168 cuc Leu / 8 
1179 cuc Leu / 8 
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GC content is another common factor leading to variation of expression 
levels in P. pastoris (Kotula et al., 1991; Sreekrishna et al” 1997). Genes with high 
AT content may be ineffectively transcribed because of premature termination 
(Romanes et al” 1992). Nevertheless, ratios of GC/AT of all S protein fragments 
were comparable; indicating that the expression level variation is contributed by 
other factors rather than GC content (Table 7.2). 
Table 7.2 一 GC contents of S protein fragments. No significant difference was 
detected between the GC contents of these fragments. 
a. a. residue of A T A T I G C ^ G C / A T 
S fragments (%) (%) (%) (%) (%) (%) ratio 
13-672 (SI) 27.3 35.3 62.6 18.2 19.2 37.4 o W 
680-1192 (S2) 30.1 29.7 59.8 18.8 21.4 40.2 0.672 
15-317 27.4 36.2 63.6 17.6 18.8 36.4 0.572 
318-510 26 .9 35.4 62.3 18.7 19 37 .7 0 .605 
587-826 28.5 32.5 61 18.3 20.7 39 0.639 
903-1187 31.8 27.8 59.6 18.5 21.9 40.4 0.678 
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7.2.3 Sizes of S Protein Fragments 
Results of SEC purification of aA-(318-510) showed that the protein native 
size was between 27 and 478 kDa, while the peak height was in the location of 
60 kDa (Figure 5.24). Its apparent molecular weight determined by SDS-PAGE was 
between 34 and 100 kDa (Figure 5.21 A). By comparison, aA-(318-510) was 
a monomeric protein but the apparent size of the glycosylated protein determined by 
SEC was higher than that determined by SDS-PAGE (Figure 5.24 and 5.25). Putative 
explanations include variations of glycan lengths, as well as the glycans in extended 
form rather than globular form. The native size was further confirmed 
after deglycosylation, however the protein became aggregated (Figure 5.26). 
This might be caused by the removal of carbohydrates, which worsens protein 
stability and leads to protein aggregation (Endo et al., 1992; Jafari-Aghdam et aL, 
2004; Wang et al., 1996). 
Sizes of de-N-glycosylated aA-(15-317), aA-(318-510) and aA-(903-1187) 
were still 5 - 1 0 kDa higher than expected and a few extra bands or smears were 
detected by SDS-PAGE (Figure 5.21). A probable reason is the presence of several 
0-linked mannose residues linking to serine or threonine residues. Another reason is 
the imconplete de-N-glycosylation by PNGase F. A sharper band may be detected 
if N-linked glycans are removed by both PNGase F and other N-glycanases such as 
Endo H and Endo F (Molhoj et al., 2001). 
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7.3 Identification of Interacting Partners 
7.3.1 Relationship between S Protein and Putative Interacting Partners 
Two mammalian proteins, Prxl and HSPA5, were preyed by using GST-Sl as 
bait (Figure 6.3). Prxl, a member of Prxs, is a thiol-specific antioxidant protein of 
26 kDa located at cytosol and nucleus. By oxidizing two active sites of cysteines to 
sulfenic acids, hydroperoxide groups (ROOH) of the substrate are reduced to alcohol 
groups (ROH). GST was proved to interact with another member containing only one 
active site (Manevich et al.’ 2004; Ralat et al., 2006). Furthermore, Prxl is present in 
the cytosol and the nucleus but not extracellular membrane. Therefore, Prxl is 
predicted to bind to GST-tag instead of being a receptor or interacting partner of 
S protein. 
Another preyed mammalian protein is HSPA5, or called glucose-regulated 
protein 78 (Grp78), which is a member of Hsp70 family located in ER (Haas, 1994; 
Wei et al, 1996). In cooperation with other chaperones including Grp94 and 
Calnexin, the major function of HSPA5 is folding, assembly and secretion of protein 
by association with shot, extended and exposed hydrophobic residues followed by 
ATP hydrolysis (Helenius, 1994; Wei et al.’ 1996). The major substrate is heavy 
chains of antibodies as well as other proteins containing short hydrophobic residues 
(Blond-Elguindi et al., 1993; Flynn et al, 1991; Hass et al” 1983). HSPA5 is 
predicted to be an interacting partner of S rather than a functional receptor as HSPA5 
is located in ER and is a chaperone likes GroEL. Since S was bound by GroEL 
during expression in E. coli, the interaction between HSPA5 and S may be due to 
exposed hydrophobic residues of the S protein. 
Besides the mammalian proteins, a few spots of 30 - 40 kDa were identified 
as GroEL and its subunits, as well as DnaJ, another bacterial chaperone (Figure 6.3). 
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Proteases presented in the lysate may be a possible answer explaining why GroEL 
with smaller sizes were present in 2D gel using GST-Sl and Vero E6 lysate 
(Figure 6.3). The proteases digest GroEL during pull-down assay but the cleaved 
GroEL products still bind to GST-S1 and were therefore detected in the 2D gel. 
Prxl and HSP5A were only present in one of the trials of pull-down assay, 
and the patterns of spots in various trials were not identical (Figure 6.3 and 6.4). 
Slight variation of the confluence and passage between batches of Vero E6 cell lysate 
may be one of the explanations for this inconsistency. Experimental errors might 
explain the difference between trials as well. 
7.3.2 Failure of Finding ACE2 
ACE2, a 120 kDa protein, was the functional receptor of SARS-CoV and 
should be found in the 2D gels generated. However, only three chaperones were 
identified while no spots could be observed in the expected location for ACE2, 
suggesting that ACE2 could not be detected by using GST-Sl with 2D gel 
electrophoresis (Figure 6.3 and 6.4). However, ACE2 could be detected by western 
blotting using aA-RBD as bait, suggesting that the condition of pull-down assay is 
capable to capture interacting partners (Figure 6.2). 
Aggregation of GST-Sl suggested that the protein might be misfolded, 
leading to the loss of function. The interaction between GST-Sl and GroEL could 
also cause the hindrance of the binding site because GroEL binds to GST-S 1 was 
in the form of cage-like structure. On the other hand, absence of ACE2 could be 
caused by the insensitivity of silver staining. The detection limit of silver staining is 
in nanogram level while that of western blotting is in pictogram level. It was possible 
that ACE2 was already captured by GST-Sl but the low protein level led to 
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the failure of detection by silver staining. Taken together, misfolding of GST-S 1 and 
insensitivity of silver staining might be the most probable reasons causing the failure. 
7.3.3 Difficulty in the Identification of Protein Spots 
Searching results of other spots only showed a number of proteins with 
low C. I. and protein score. Coverage and the number of peaks matching to these 
proteins were low as well, thus most of samples were unidentified (Table 7.2). 
Major reasons causing such failure is related to the sample preparation and the errors 
from the MALDI-TOF-TOF technique. 
Protein amount is an important criterion determining whether identification is 
successful or not. In general, the identification of a spot or band with a larger amount 
is easier because a higher amount of protein leads to a higher peak intensity, 
resolution and signal-to-noise (S/N) ratio (Table 7.3). In our experience, 
some peptides can only be detected when protein levels are high. Moreover, 
more matching peptides increase the chance of spot identification. Sufficient 
amounts of proteins improve the numbers and intensities of peptides subjecting to 
MS/MS, leading to more accurate results. Hence, the recombinant proteins 
(GST-Sl and GST) and bacterial proteins (GroEL), but not other proteins with 
a low level from Vero E6 cells, could be identified in most of our 2D gels. One of 
the methods that can solve this problem is to pool protein spots from many trials of 
experiments in order to increase the protein amounts. 
On the other hand, more than 50 spots were presented in a 2D gel using 
GST-Sl as bait (Figure 6.3 and 6.4). There will be a chance that a protein spot 
contains a few proteins rather than a single protein. PMF containing more than 
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one set of peptides is more difficult to be analyzed. Using two or more 2D gels with 
various percentages, such as 8 % and 15 % might resolve the spots. 
A possible reason, which can explain why only recombinant proteins and 
bacterial proteins but not proteins from Vero E6 cells could be identified, 
is the post-translational modifications of Vero E6 cell proteins. Any modification 
changing peptide masses may lead to the failure in spot identification. Even if partial 
modifications are considered before searching, some complicated modifications 
such as glycosylation are difficult to be predicted. Furthermore, probability of 
glycosylated peptide ionization is relatively lower and thus the number of peptides 
generated will be reduced. Moreover, the inclusion of unrelated modifications during 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.4 - Cluster areas, peak areas and S/N ratios of selected proteins. 
The average cluster area, peak area and S/N ratio of matched masses of GST with 
larger protein amount were higher than that of HSPA5 with smaller protein amount. 
~ GST (Spot #23 in Figure 6.3 A) HSP5A (Spot #2 in Figure 6 3 A) 
Observed I Cluster P e a k ^ Observed Cluster Peak S ^ 
Mass Area Area ratio Mass Area Area ratio 
2 0 4 5 . 0 2 6 " “ 4 8 3 7 0 0 1 6 0 3 1 4 1 5 8 4 1 5 6 6 . 7 7 1 5 " “ 5 T l 4 2 " " “ 2 1 7 8 3 H I T " 
2269.12 80758 23591 251.5 1815.9972 41154 15957 274.4 
1516.811 65125 27039 366.3 2165.0042 20467 5705 148 
1032.609 56507 30500 487.7 2235.1738 16137 4750 110.7 
1801.945 54815 20696 228.5 1833.9081 15901 5666 88.1 
2357.182 17759 5898 52.8 1512.7531 10387 4121 79.1 
2326.023 10961 4265 34.2 986.5270 7020 7020 31.9 
1182.615 5920 2805 47.8 1887.9775 6462 2305 39.5 
1182.738 5850 3058 42.2 1934.0231 5315 2376 45.5 
1094.585 5512 2982 45.3 1588.8052 4060 4060 24 




spike protein SI and S2 domains as well as four fragments were expressed in 
E. coli and P. pastoris. After expression condition optimization, GST-Sl was 
expressed in E. coli strain BL21, 16 °C overnight and then lyzed in PBS. The yield of 
soluble GST-Sl purified by affinity chromatography and SEC was approximately 
100 |ig/L. S protein associated with GroEL and some non-target proteins forms 
protein aggregates. GroEL, but not other unrelated proteins, was removed by 
the addition of 2 M urea in PBS. On the other hand, soluble aA-(318-510) with 
a yield of 46 mg/L was secreted from P. pastoris and the yield reached a maximum 
after 144 hours of induction. The production yields of other S domains and fragments 
were much lower. Native aA-(318-510) was a monomer but became aggregates after 
de-N-glycosylation. The result implied ACE2 could be captured by pull-down assay 
using native aA-(318-510). 
Three interacting partners, Prxl, HSPA5 and DnaJ, from Vero E6 cell lysates 
were identified after pull-down assay using GST-Sl as bait, followed by 2D gel 
analysis and mass spectrometry; however, they may only interact with the GST-tag 
and S protein hydrophobic residues respectively instead of being functional receptors. 
Moreover, bacterial GroEL subunits were identified. They may be the digestion 
products of GroEL by protease in Vero E6 cell lysates. Lastly, some spots observed 




7.5 Future Prospects 
GST-S proteins produced in E. coli were bound by GroEL. After 
optimizations and purifications, they were still associated with non-target proteins in 
form of aggregation. Moreover, effects of glycosylation and deglycosylation on 
aA-(15-317), aA-(318-510) and aA-(903-l 187) were not yet understood. It is 
unknown whether these S proteins are in native conformation and functional. 
The pull-down assay will be performed in order to determine whether the S protein 
specifically interacts with ACE2 or other proteins. On the other hand, since aA-Sl 
and aA-S2 failed to be produced and insoluble respectively, the expression 
conditions such as lowering expression temperature, altering MeOH concentration 
and using strains other than KM71H will be optimized to increase both expression 
levels and solubility. 
In order to identify the putative interacting partners successfully, several 
methods will be tried including the increase in the protein amount by repeating 
the pull-down assay, followed by pooling spots from 2D gels for mass spectrometric 
analysis. Also, 2D gels with various percentages will be performed to ensure that 
each spot contains only one protein instead a mixture of many proteins. 
As S recombinant proteins were expressed in bacteria and yeast rather than 
the mammalian system, the post-translational modification and protein folding of 
different expression systems are varied. Consequently, if some putative functional 
receptors will be identified by pull-down assay, the interaction will be further 
validated by co-immunoprecipitation using S and the putative receptors expressed in 






Leu Glu Val Leu Phe Gln^Gly Pro Leu Gly Ser Pro Glu Phe Pro Gly Arg Leu Glu Arg Pro His 
CT6 GAA GTT CTG TTC GAG GGG CCC CTGGGA TCC.CCGGAA H C C C G GGT CGA^CTC GAGCGG CCG CAT 
BamH I EcoR I sma I Sal I xho I Not I 
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\ / A n p a 1(1828) 
ANVN 1(3040) - - A . ！^ 
B S S S L ( 3 3 ( » 7 > P S F ^ 丨 ( 糊 
BSPLU11 liS^JjAV.. 1(2187) 
Sap 1(3108) \ \ F s p 1(2205) 
Bst1107 1(29均 r r ^ \psp5 11(2230} 
Tthin 1(2869)/ 
T7 prtwiotef primer #69348-3 
？ ^ i T S r 析 抑 胶 T Z p r a m o t e r • " Ui c o p ^ ^ xb.l rt>s 
AGALCFCSA1CCCGC8:FTAANAATACSACLCI«;FAL^ASGSSAAIAAIGASCGSA!AATAAT!CCCCLT LASA^^ATA/UF NCRITAATT ITFTAGAACSAGA 
jVcQl His*Tag Nhfi TT'Taq 
?<:CI;SLYGFFRS»RH:IS^IAHI5!HT^M»HUA:$ERS»RSLYLGWVQLT^RO&RFSLYS»RHI，H«TALOS<GRBISTLIHRGLYSLYGLRSLN 
samtLi^ sgEL-Sasi ^ L J2>aL 妝 
...GSrCSGSAfCCeAAMCCftSC ICCGrceACAAGCnSCSStCaCACVCOAGCACtACCACCACCACCAC IfiAGAlCCaCCtGCUACAAAGCCC 
..,WrCWAfCtGMnCSAMICC§!C<5AUAGCnSC驳CCSCACtCSW5CACCM;CAUAtCACCACt<2ASA�CCSSCt(SC ！ AA^AAAGCCC pfcb拥t卜） 
Bptft102i Trteretin^ 
T7 t«fmhT»tw phmer #00^7-3 
pET-28a-c(+) cloning/expression region 




p R H i s M B P R e s t r i c t i o n M a p 
4060 base pairs 
Restrictioit Enayme Kap: 
T7 promoter 
DI, O P A K l , I R L T I G R P Q R F P S R N N E ' V * ! . 
i GftTCTCGA'rCCCGCGAAATTAiMrAOaiCnatCTniTAGGGA&ACCAeftACgGTTrCXCrCrflGAAATAATTTTGTrAACr 8 0 
i CTftGAGC?;iVGGGCGCTTTAATTATGCTGftG?GATATCCCTCTGGTGTTGCCAAAGGGAGATC"mATTAAAACAAArGA 80 
Start ex His-tag -> MBP 
* E G D I H M G R G S H H H H H H G L A M K T E E G 
81 TTftA(^ ;^GAGA.r^CM.Aro<S«(:CGa;CTr(:TCAT(:ftn:ATCATC/m:ATGGTCTGgCT>VrGAAAM:TGRAGftRGGTA 16G 
81 AATTCTTCCTCTATATGTRTACCC6GCCCCAAGAGTAGTA(rAGTACrAGTRCCRGACCGftTACTTTTGACTTCTTCCAT 160 
Ndel -
Throtnbin site 
N i. G I E G Ft A V J» jg C S P G I l , * S R P A G K L O 
1231 O-WXTCGGGATCGAGGGAASGCTGGTTCCGCGTGGATCCCCGGGAATTCTCTAGAGTCGACCrCCAeGCAfVGCTTGATC 1360 
1281 G'fTGGi^GCCCTJWSCTCCCrCCGACCAAGGCGCACCTAGGGGCfXTTAAGAGATCTCAGCTGGACOTCCGTtCGAACTAC； 1360 




P A A N K A R K f c l A E L A A A T A K Q * ! . A * P l . GR 
1361 CC;GCTGCTAACftMGCC<XM>AGGA?VGCTGAGTTGGCTGCTGCC*Qa?CTO*gaurJUU：狄(K^ftTAftXCCTTGGGGCC 1440 
13 6.1 GCCGACGATTGTTTCGGacrTCCTTCGACTCARCCGACGACGGTGGCGRCTCGTTATTGATCG7ATT(K;GGftACCCCGG lA-JC 




^ 一 CP 
I ^ 
\ 3 : 6 k b M 
Comments for pPICZot A Sg/ir W 
3593 nucleotides ^ ^ g f l i l M M y V ^ 
5' A0X1 promoter region: bases 1-941 * ftrfi is in Version B only 
5' A0X1 priming site： bases855-875 dalismVersionConly 
a-factor signal sequence: bases 941-1207 
Multiple cloning site; bases 1208-1276 
c-myc epitope: bases 1275-1304 
Polyhistidine {6xHis) tag: bases 1320-1337 tihe two Xhoi sites in the vector allow 
3' AOXI priming site： bases 1423-1443 the user to clone their gene in frame with 
AOXI transcription termination region: bases 1341-1682 the Kex2 deavage site, resulting in 
TEF1 promoter： bases 1683-2093 e>qjression of their native gene without 
EM7 promoter； bases 2095-2162 additional amino adds at the N-tenninus. 
Sh ble ORF: bases 2163-2537 
CYC1 transcription termination region: bases 2538-2855 
pUC origin; bases 2866-3539 (complementary strand) 
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5' end of A0X1 mRNA 5' A0X1 priming site 
I I 
811 AACCTTTTTT TTTATCATCA TTATTAGCTT ACTTTCATAA TTGCGACTGG TTCCAATTGA 
1 
871 CAAGCTTTTG ATTTTAACGA CTTTTAACGA CAACTTGAGA AGATCAAAAA ACAACTAATT 
I 
931 ATTCGAAACG ATG AGA TTT CCT TCA ATT TTT ACT GCT GTT TTA TTC GCA GCA 
Met A r g Phe P r o S e r l i e P h e T h r A l a V a l L e u P h e A l a A l a 
983 TCC TCC GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA 
S e r S e r A l a Leu A l a A l a P r o V a l Asn T h r T h r T h r G l u A s p G l u T h r A l a 
a-factor signal sequence 
1034 CAA ATT CCG GCT GAA GCT GTC ATC GGT TAG TCA GAT TTA GAA GGG GAT TTC 
G i n l i e P r o A l a G l u A l a V a l l i e G l y T y r S e r A s p L e u G l u G l y A s p Phe 
1085 GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTT 
A s p V a l A l a V a l Leu P r o P h e S e r Asn S e r T h r Asn A s n G l y L e u L e u Phe 
xhor 
1136 ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA TCT CTC 
l i e Asn T h r T h r l i e A l a S e r H e A l a A l a L y s G l u G l u G l y V a l S e r Leu 
Kex2sign| cleavage ECORI Pml\ SJM BsmBIAsp718l 
1187 GAG AAA AGA GAG GCT GAA GC@ GAATTCAC GTGGCCCAG CCGGCCGTC TCGGATCGGT 
G l u L y s A r g G l u A l a j ^ G l u A l a ^ 
Ste13 signal cleavage 
Kpn I Xho I Sac II Not I Xba I c-myc epitope 
1244 ACCTCGAGCC GC'GGCGGCC GCCAGCTTTC TA GAA CAA AAA CTC ATC TCA GAA GAG 
G l u G i n L y s L e u l i e S e r G l u G l u 
polyhistidine tag 
1299 GAT CTG'AAT AGC GCC GTC GAC CAT CAT CAT CAT CAT CAT' TGA GTTTGTAGCC 
A s p L e u A s n S e r A l a V a l A s p H i s H i s H i s H i s H i s H i s * * * 
1351 TTAGACATGA CTGTTCCTCA GTTCAAGTTG GGCACTTACG AGAAGACCGG TCTTGCTAGA 
3' A0X1 priming site 
1411 TTCTAATCAA GA'GGATGTCA GAATGCCATT TGCCTGAGAG ATGCAGGCTT CATTTTTGAT 
3' polyadenylation site 
1471 ACTTTTTTAT TTGTAACCTA TATAGTATAG GATTTTTTTT GTCATTTTGT TTCTTCTCGT 
Figure 8.4 - Vector map of pPICZa-A (Adapted and modified from http://www. 
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